🏷

Classifications

Harrison's Chapter

👪

Inheritance

1

X-linked inheritance HP:0001417

The pattern is X-linked but is best described as semidominant rather than cleanly recessive or dominant, and the sources genuinely disagree on the label. Hemizygous males are consistently and more severely affected; carrier females are frequently not normal but mildly affected, with mild cognitive impairment and speech difficulties, and at least one heterozygous female has developed the full neuropsychiatric picture with regression, pyramidal signs and parkinsonism. Dotti and colleagues therefore described the index family as X-linked semidominant. OMIM/MedGen annotate MONDO:0010235 as X-linked dominant, while the MONDO synonym list also carries an X-linked recessive designation inherited from the MRXS13 nomenclature. The generic HP:0001417 term is used here deliberately rather than forcing a choice between HP:0001419 and HP:0001423, with the semidominant reality described in prose. Expressivity is recorded as VARIABLE on the strength of the explicit intrafamilial variability reported in the Belgian family, and penetrance as INCOMPLETE because carrier females range from unaffected to fully symptomatic.

X-linked inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE

Show evidence (4 references)

PMID:11805248 SUPPORT Human Clinical

"The authors recently described a novel A140V MECP2 missense mutation in an Italian family with X-linked semidominant mental retardation."

The explicit semidominant characterisation that this block is built on.

PMID:11805248 SUPPORT Human Clinical

"The neurologic disorder associated with A140V MECP2 mutation is not necessarily lethal in men, but they are more severely affected than women of the same family."

Establishes the sex-severity gradient within a single pedigree, the core empirical observation the inheritance model rests on.

PMID:27465203 SUPPORT Human Clinical

"We further delineate the phenotype associated with the p.Ala140Val mutation, illustrating a variable expressivity even within a given family"

Direct support for the VARIABLE expressivity annotation.

+ 1 more reference

◈

Mechanistic Hypotheses

1

ATRX mislocalisation as the proximate cause of the PPM-X phenotype

atrx_mislocalization_model EMERGING

Evidence balance 1 support

The dominant mechanistic model for this disorder is that PPM-X is, at the chromatin level, a partial phenocopy of ATR-X syndrome produced from the MeCP2 side of the interaction. Because p.Ala140Val leaves methyl-CpG reading and heterochromatic targeting intact and its only measurable defect is failure to recruit ATRX, the neurological consequences should follow from ATRX being in the wrong place rather than from loss of MeCP2 transcriptional function. The model is supported by biochemistry and by the observed clinical overlap between the two syndromes (intellectual disability, microcephaly, spasticity, dysmorphism), but it has not been tested directly: no study has asked whether restoring ATRX targeting rescues the A140V phenotype, ATRX localisation has not been reported in the allele-matched mouse, and the alpha-thalassemia and urogenital features of ATR-X syndrome are absent from PPM-X, so the phenocopy is at best partial.

Pathograph links

MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant -> Selective Loss of ATRX Recruitment with Preserved Methyl-CpG Binding

Selective Loss of ATRX Recruitment with Preserved Methyl-CpG Binding -> Disrupted Neuronal Maturation and Dendritic Arborization

Show evidence (1 reference)

PMID:17296936 SUPPORT In Vitro

"We propose that disruption of the MeCP2-ATRX interaction leads to pathological changes that contribute to mental retardation."

The authors state the hypothesis in exactly these terms, and mark it as a proposal rather than a demonstrated mechanism.

?

Discussions and Knowledge Gaps

3

What causes macroorchidism in PPM-X syndrome, and is it actually a consistent feature of the MECP2 p.Ala140Val phenotype?

KNOWLEDGE GAP OPEN ppmx_macroorchidism_mechanism

Attached to

pathophysiology#MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant

Macroorchidism is one of the four letters of the syndrome acronym, but it is the weakest-evidenced component of the entity. It appears in the 1996 founding description and is retained in the GeneReviews characterisation, yet none of the four subsequently reported A140V families - Siena, MRX79, the Belgian four-generation family, or the sporadic cases - reports testicular volumes or counts affected males with macroorchidism, and the allele-matched mouse model has not been examined for a testicular phenotype. No mechanism has been proposed linking loss of MeCP2-ATRX recruitment to testicular enlargement. Because macroorchidism is simultaneously the feature that names the syndrome and the feature that drives confusion with fragile X, the gap matters for both entity definition and differential diagnosis. It is the reason no frequency band is asserted for this phenotype.

Proposed experiments

Systematic testicular volume survey across MECP2 A140V pedigrees

exp_ppmx_orchidometry_pedigree_survey

Measure testicular volume by orchidometry or ultrasound in all postpubertal males from the known MECP2 p.Ala140Val pedigrees (Newcastle PPM-X, Siena, MRX79, Belgian four-generation family) and in reported sporadic carriers, reporting against age- and ancestry-matched normative data. This converts the qualitative founding observation into a countable phenotype with a denominator, which is what a frequency band would require.

Readouts

Testicular volume relative to age-matched norms

pathophysiology#MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant

Macroorchidism HP:0000053

orchidometry scrotal ultrasonography

Direction: POSITIVE

Testicular phenotyping of the Mecp2 A140V knock-in mouse

exp_ppmx_mouse_testicular_phenotype

Compare testis weight, seminiferous tubule histology and Sertoli-cell counts in adult male Mecp2 A140V knock-in mice against wild-type littermates. The line has a normal lifespan, so adult reproductive phenotyping is feasible; no testicular readout has been reported for it.

Readouts

Testis weight and seminiferous tubule histology

pathophysiology#MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant

Macroorchidism HP:0000053

histopathology

Direction: POSITIVE

Show evidence (1 reference)

PMID:8651288 SUPPORT Human Clinical

"The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."

The only primary clinical description of the testicular phenotype, and it is qualitative - no volumes, no counts.

Is PPM-X a distinct syndrome, or simply the most fully ascertained end of a single MECP2 p.Ala140Val phenotype that is otherwise reported as nonsyndromic X-linked intellectual disability?

KNOWLEDGE GAP OPEN ppmx_entity_boundary_vs_nonsyndromic_xlid

Attached to

pathophysiology#Cognitive and Neuropsychiatric Dysfunction

The same allele has been reported under three different nosological labels: PPM-X (a named syndrome), MRX79 (nonsyndromic X-linked intellectual disability), and "X-linked intellectual disability with spasticity". MONDO has already folded MRX79 into MONDO:0010235 as a synonym, which implicitly settles the question by lumping - but the lumping was nomenclatural rather than the result of a systematic phenotypic reassessment. A caution on the MONDO synonym list, which is itself a same-gene blending trap: MONDO:0010235 also carries "mental retardation, X-linked 16" (MRX16), but the MRX16 family does NOT carry A140V - Couvert and colleagues identified a different MECP2 allele, E137G, in that family (PMID:11309367). MRX16 was merged into this MONDO entity by nomenclature, not on allelic grounds, and it is deliberately excluded from the A140V pedigree counts and from the proposed experiments below. The defining psychiatric and testicular features come almost entirely from the single founding pedigree, while the motor phenotype replicates robustly across families. It is therefore unresolved whether psychosis and macroorchidism are allele-level features that were simply not looked for in the families ascertained as nonsyndromic, or genuine family-specific modifiers. This is a live curation question, because if the former is true the entity is well defined and underdiagnosed, and if the latter is true the honest entity is "MECP2 p.Ala140Val-related X-linked intellectual disability with spasticity" and PPM-X is a historically privileged pedigree.

Proposed experiments

Protocolised psychiatric reassessment of A140V pedigrees ascertained as nonsyndromic

exp_ppmx_blinded_psychiatric_reassessment

Apply a structured diagnostic interview for affective and psychotic episodes, adapted for intellectual disability, to all adult carriers in the MRX79 family and in other A140V pedigrees originally ascertained as nonsyndromic, with raters blind to the historical syndrome label. If psychosis is found at rates comparable to the founding family, the entity is confirmed as underdiagnosed rather than pedigree-specific.

Readouts

Lifetime prevalence of affective psychotic episodes

pathophysiology#Cognitive and Neuropsychiatric Dysfunction

Psychosis HP:0000709

Direction: POSITIVE

Genotype-first ascertainment of MECP2 A140V carriers from sequencing biobanks

exp_ppmx_genotype_first_biobank_phenotyping

Identify MECP2 c.419C>T carriers in large population and clinical sequencing biobanks and phenotype them prospectively, blind to the PPM-X literature. Genotype-first ascertainment removes the referral bias that produced the original syndrome definition and is the only design that can estimate the true penetrance of the psychiatric and testicular features.

Readouts

Penetrance of psychosis, macroorchidism and spastic paraparesis in unselected carriers

pathophysiology#Cognitive and Neuropsychiatric Dysfunction

Direction: POSITIVE

Show evidence (2 references)

PMID:12325019 SUPPORT Human Clinical

"We mapped a new non-syndromic X-linked family (MRX79) to the chromosomal region Xq27.3-Xq28 and identified an A140V mutation in the MEPC2 gene in all patients with the disease haplotype."

The same allele described as causing explicitly non-syndromic intellectual disability, which is the crux of the boundary question.

PMID:27465203 SUPPORT Human Clinical

"We further delineate the phenotype associated with the p.Ala140Val mutation, illustrating a variable expressivity even within a given family, and we compare our patients with previous reported cases in the literature."

Documents variable expressivity within a family, which is the mechanism by which one allele could plausibly generate both the syndromic and the nonsyndromic presentations.

Does the Mecp2 A140V knock-in mouse model PPM-X syndrome, or does it model the mild end of Rett syndrome? Neither of the two features that define PPM-X clinically - psychosis and macroorchidism - has been demonstrated in it, and ATRX localisation, the proposed mechanism, has never been assayed in it.

HUMAN MODEL MISMATCH OPEN ppmx_mouse_model_translational_validity

Attached to

pathophysiology#Disrupted Neuronal Maturation and Dendritic Arborization pathophysiology#Hippocampal Network Hyperexcitability and Impaired Synaptic Plasticity

All cellular and circuit-level evidence in this entry comes from one mouse line, and that line is consistently framed by its own creators as a model of "Rett syndrome/X-linked mental retardation", with PPM-X mentioned only as one of the human phenotypes the allele can produce. The reported phenotypes - increased cell packing density, reduced dendritic complexity, reduced soma size, hippocampal hyperexcitability, aged-onset LTP deficits - are generic MeCP2-dysfunction readouts shared with null models, not PPM-X-specific ones. No published work has looked for a behavioural correlate of affective psychosis in the line, nor for a testicular phenotype, and its spastic-paraparesis status is not reported either. The mismatch is mechanistically meaningful rather than pedantic: the whole argument that PPM-X is separable from Rett rests on the ATRX-recruitment selectivity of the allele, which has been demonstrated only in vitro and in fibroblasts, and the mouse work does not test whether ATRX mislocalisation is what produces the phenotypes observed. Any claim in this entry sourced from the mouse is therefore marked MODEL_ORGANISM and is not used to support a human phenotype on its own.

Proposed experiments

ATRX subnuclear localisation in Mecp2 A140V knock-in brain

exp_ppmx_atrx_localisation_in_vivo

Assay ATRX localisation to pericentric heterochromatin in neurons from Mecp2 A140V knock-in mouse brain by immunofluorescence and chromatin fractionation, versus wild-type littermates. This tests whether the in vitro and cultured-fibroblast recruitment defect that the entire mechanistic model rests on actually holds in vivo in the allele-matched animal.

Readouts

Fraction of neurons with ATRX at heterochromatic foci

pathophysiology#Selective Loss of ATRX Recruitment with Preserved Methyl-CpG Binding

heterochromatin organization GO:0070828 ⚠ ABNORMAL

Direction: NEGATIVE

Psychosis-relevant and motor phenotyping of the Mecp2 A140V line

exp_ppmx_mouse_neurobehavioural_battery

Run a neurobehavioural battery on the A140V line covering (a) psychosis-relevant endophenotypes - prepulse inhibition, amphetamine sensitivity, circadian activity cycling - which have never been reported for this model, and (b) corticospinal motor function - rotarod, gait analysis, hindlimb clasping, with corticospinal tract histology - to test whether the mouse reproduces the most robustly replicated human feature, progressive spastic paraparesis. Together these determine whether the line is a PPM-X model or only a generic mild MeCP2 model.

Readouts

Prepulse inhibition and amphetamine-induced hyperlocomotion

pathophysiology#Cognitive and Neuropsychiatric Dysfunction

Direction: NEGATIVE

Age-dependent gait and hindlimb motor decline

pathophysiology#Progressive Corticospinal and Extrapyramidal Dysfunction

Spastic paraparesis HP:0002313

Direction: POSITIVE

Show evidence (2 references)

PMID:20163734 PARTIAL Model Organism

"We have identified various neurological abnormalities in this mouse model of Rett syndrome/X-linked mental retardation which may help to elucidate the manner in which MECP2 mutations cause neuronal changes resulting in mental retardation without the confounding effects of seizures, chronic..."

Marked PARTIAL: the authors frame the line as a Rett/XLMR model and restrict their claim to generic MECP2-related neuronal changes, not to PPM-X-specific features.

PMID:24750778 PARTIAL Model Organism

"which provides new insights into the understanding of the pathogenesis of Rett syndrome"

Marked PARTIAL: the electrophysiology paper explicitly frames its contribution as insight into Rett syndrome pathogenesis, not PPM-X, despite using the PPM-X allele.

⚙

Pathophysiology

6

MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant

The lesion is a single recurrent missense allele, c.419C>T p.(Ala140Val), in the MECP2 gene at Xq28. Unlike most Mendelian entries this disorder has effectively an allele series of one: every reported PPM-X or A140V family carries the same substitution, which sits in the alpha-1 helix of the methyl-CpG-binding domain. It is a genuine recurrent mutation rather than a rare polymorphism - it segregates with the disease haplotype in multiple unrelated multiplex pedigrees and is enriched in male intellectual-disability cohorts - and it accounts for roughly 0.6% of all reported MeCP2 variants. Hemizygous males are affected; heterozygous females are normal or mildly affected.

ATRX mislocalisation as the proximate cause of the PPM-X phenotype

MECP2 hgnc:6990

Downstream

Selective Loss of ATRX Recruitment with Preserved Methyl-CpG Binding

Show evidence (4 references)

PMID:11885030 SUPPORT Human Clinical

"We report here the genetic cause of the X-linked syndrome of psychosis, pyramidal signs, and macro-orchidism (PPM-X) in a three-generation family manifesting the disorder as a mutation in the methyl-CpG binding-protein 2 (MECP2) gene in Xq28."

The gene-assignment paper and the strongest identity anchor for this entry: it binds the PPM-X acronym directly to MECP2 at Xq28, and it did so in the same family that Lindsay and colleagues used to define the syndrome.

PMID:11885030 SUPPORT Human Clinical

"This strongly suggests that A140V is a hot spot of mutation resulting in moderate to severe MR in males."

Establishes A140V as a recurrent hot-spot allele rather than a private family variant.

PMID:12325019 SUPPORT Human Clinical

"In addition to data published by others, this suggests that A140V is a recurrent mutation (and not a polymorphism) found in patients with X-linked mental retardation."

Independent confirmation of recurrence and, importantly, an explicit statement that the allele is pathogenic rather than a benign variant - the question that dominated the early A140V literature.

+ 1 more reference

Selective Loss of ATRX Recruitment with Preserved Methyl-CpG Binding

This is the discriminating node of the entry and the reason PPM-X is mechanistically separable from Rett syndrome despite sharing a gene. MeCP2 normally binds methylated CpG dinucleotides and, in a DNA-methylation-dependent manner, recruits ATRX - a SWI2/SNF2 helicase/ATPase chromatin remodeller, itself the ATR-X syndrome gene - to heterochromatic foci. The ATRX-interacting domain of MeCP2 overlaps the methyl-CpG-binding domain, and MBD point mutations causing either Rett syndrome or X-linked intellectual disability inhibit the ATRX interaction. What is distinctive about p.Ala140Val is not that it spares methyl-CpG binding - the Rett allele R133C does that too - but that loss of the ATRX interaction is its ONLY measurably altered property: it binds methylated DNA normally, targets heterochromatin efficiently, and, unlike R133C, does not acquire aberrant binding to non-methylated DNA. That makes it the cleanest natural separation-of-function allele in MeCP2. Two consequences follow. Mechanistically, the phenotype of PPM-X can be attributed largely to mislocalised ATRX rather than to failed methyl-CpG reading. Clinically, this hypomorphic, function-selective character is the most plausible explanation for the sex-reversed severity pattern relative to Rett syndrome - hemizygous males survive with moderate intellectual disability instead of dying of neonatal encephalopathy, while heterozygous females are normal or only mildly affected instead of having classic Rett syndrome.

ATRX mislocalisation as the proximate cause of the PPM-X phenotype

MECP2 hgnc:6990

MECP2 hgnc:6990 ATRX hgnc:886

heterochromatin organization GO:0070828 ⚠ ABNORMAL

methyl-CpG binding GO:0008327

Downstream

Disrupted Neuronal Maturation and Dendritic Arborization

Show evidence (7 references)

PMID:17296936 SUPPORT In Vitro

"We report that MeCP2 interacts with ATRX, a SWI2/SNF2 DNA helicase/ATPase that is mutated in ATRX syndrome (alpha-thalassemia/mental retardation, X-linked)."

Establishes the MeCP2-ATRX interaction that this node is built on.

PMID:17296936 SUPPORT In Vitro

"Point mutations within the methylated DNA-binding domain of MeCP2 that cause Rett syndrome or X-linked mental retardation inhibit its interaction with ATRX in vitro and its localization in vivo without affecting methyl-CpG binding."

The abstract-level statement of the separation of function: MBD point mutations, including the XLMR allele tested here, kill ATRX binding while leaving methyl-CpG binding intact.

PMID:17296936 SUPPORT In Vitro

"Neither the R133C nor the A140V mutations affected binding to methylated DNA"

Direct experimental demonstration, in the full text, that A140V specifically preserves methylated-DNA binding - the "preserved" half of this node.

+ 4 more references

Disrupted Neuronal Maturation and Dendritic Arborization

Downstream of the chromatin lesion the affected cell type is the neuron, and the defect is one of maturation rather than survival. In the A140V knock-in mouse, cortical and hippocampal neurons are packed more densely and their dendritic trees are significantly less complex than wild type. Cultured hippocampal and cerebellar granule neurons from the same model have smaller somata, and this size deficit is cell-autonomous: in heterozygous females carrying a wild-type allele marked with eGFP, only the neurons expressing the mutant allele are small. The size phenotype tracks with down-regulation of mTOR signalling and is rescued in vitro by IGF-1. Note that all of the cellular evidence at this node is from the mouse knock-in or from cultures derived from it. No human neuropathology or patient-derived neuronal model of p.Ala140Val has been published, and the mouse is described by its makers as a Rett syndrome / XLMR model rather than a PPM-X model - see the HUMAN_MODEL_MISMATCH discussion.

neuron CL:0000540 hippocampal pyramidal neuron CL:1001571 cerebellar granule cell CL:0001031

dendrite development GO:0016358 ↓ DECREASED TOR signaling GO:0031929 ↓ DECREASED

Downstream

Hippocampal Network Hyperexcitability and Impaired Synaptic Plasticity

Progressive Corticospinal and Extrapyramidal Dysfunction

Show evidence (5 references)

PMID:20163734 SUPPORT Model Organism

"The abnormalities found include increases in cell packing density in the brain and a significant reduction in the complexity of neuronal dendritic branching."

The primary structural finding in the allele-matched mouse model.

PMID:27781091 SUPPORT In Vitro

"Cultured hippocampus and cerebellar granule neurons from mutant animals were significantly smaller than neurons from wild type animals."

Establishes the reduced-soma-size cellular phenotype in two neuronal populations. Tagged IN_VITRO rather than MODEL_ORGANISM because the measurement is in primary cultures derived from the mice, not in the intact animal - the authors themselves call it "an important in vitro cellular phenotype".

PMID:27781091 SUPPORT In Vitro

"the size of neurons expressing the mutant (A140V) allele also showed a significant reduction compared to neurons expressing wild type MeCP2, supporting a cell-autonomous role for MeCP2 in neuronal development"

The mosaic-female culture experiment showing the defect is cell-autonomous, which matters because it argues the neuronal phenotype is not a secondary consequence of a sick brain environment. IN_VITRO: cultured neurons from doubly heterozygous females.

+ 2 more references

Hippocampal Network Hyperexcitability and Impaired Synaptic Plasticity

The structural changes translate into a shifted excitation/inhibition balance that is age-dependent. Young A140V mice already show intrinsic hyperexcitability of CA1 pyramidal neurons - depolarised resting membrane potential, higher firing rates, broader action potentials, smaller afterhyperpolarisation - together with a synaptic signature pointing the same way: fewer spontaneous inhibitory postsynaptic currents and a higher probability of evoked glutamate release. Long-term potentiation at CA3-CA1 synapses is intact at this stage. Only in aged mice does plasticity fail, with deficits in both short-term and long-term potentiation appearing on top of the persisting hyperexcitability. This sequence - hyperexcitability first, plasticity failure later - is the cellular correlate of a disorder that is not a static encephalopathy: the human phenotype is a slowly progressive spastic and extrapyramidal syndrome, and in at least one reported individual there was frank adolescent-onset regression.

hippocampal pyramidal neuron CL:1001571

modulation of chemical synaptic transmission GO:0050804 ⚠ ABNORMAL

Downstream

Cognitive and Neuropsychiatric Dysfunction

Show evidence (3 references)

PMID:24750778 SUPPORT Model Organism

"hippocampal CA1 pyramidal neurons exhibited more positive resting membrane potential, increased action potential (AP) firing frequency induced by injection of depolarizing current, wider AP duration, and smaller after hyperpolarization potential compared to neurons prepared from age-matched..."

The intrinsic-excitability half of the node, in young mice.

PMID:24750778 SUPPORT Model Organism

"At the synaptic level, A140V mutant neurons exhibited a reduced frequency of spontaneous IPSCs (inhibitory postsynaptic potentials) and an enhanced probability of evoked glutamate release, both suggesting neuronal hyperexcitation."

The synaptic half of the node - reduced inhibition plus increased excitatory release probability.

PMID:24750778 SUPPORT Model Organism

"In adult mice (11- to 13-month-old), in addition to neuronal hyperexcitation, we also found significant deficits of both short-term and long-term potentiation of CA3-CA1 synapses in A140V mice compared to WT mice."

Establishes the age-dependence: plasticity failure is a late addition, not a developmental given. This is the evidence for the "progressive" framing of this node.

Progressive Corticospinal and Extrapyramidal Dysfunction

The motor arm of the syndrome and the "PP" of the acronym. All six symptomatic relatives in the Siena A140V family - four men AND two women - had slowly progressive spastic paraparesis/pyramidal signs together with distal atrophy of the legs, with ataxia and postural hand tremor in a subset and dysarthria in the oldest affected brothers. That the two heterozygous women were also affected motorically is important: the motor syndrome is not male-restricted, only male-predominant in severity. The independently ascertained Belgian four-generation family reproduced the same picture - slowly progressive spastic paraparesis with dystonic hand movements - which is the strongest available evidence that the motor syndrome is an allele property and not a single-family peculiarity. Parkinsonian features were part of the founding description and remain in the syndrome definition, though they are less consistently reported in the later families than the pyramidal findings.

neuromuscular process controlling posture GO:0050884 ⚠ ABNORMAL

Show evidence (3 references)

PMID:11805248 SUPPORT Human Clinical

"Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."

The best-quantified neurological description of the A140V phenotype, and the source of the frequency derivations for the motor phenotypes.

PMID:27465203 SUPPORT Human Clinical

"Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."

Independent replication of the progressive spastic paraparesis in an unrelated family, which is what upgrades this from a single-pedigree observation to an allele-level phenotype.

PMID:8651288 SUPPORT Human Clinical

"The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."

The founding description, and the source of the pyramidal and parkinsonian components of the syndrome name.

Cognitive and Neuropsychiatric Dysfunction

The cognitive and psychiatric arm, and the "P" and "X" of the acronym. Intellectual disability is present in every reported hemizygous male and is typically moderate, with impaired language development; carrier females are normal or have mild cognitive impairment and speech difficulties. Layered on this is an episodic affective psychosis: four of the six affected males in the founding family had episodes of manic-depressive psychosis, which is the feature that gave the syndrome its first letter and distinguishes it from nonsyndromic X-linked intellectual disability. The psychiatric component is age-dependent rather than congenital - it emerges in adolescence or adult life on a background of stable developmental disability - and it has now been described in a heterozygous female as well, who presented with late-onset cognitive regression alongside pyramidal signs, parkinsonism and bipolar symptoms.

learning or memory GO:0007611 ⚠ ABNORMAL

Show evidence (3 references)

PMID:8651288 SUPPORT Human Clinical

"Four of the six moderately retarded males have had episodes of manic-depressive psychosis."

The defining psychiatric observation of the syndrome, with an explicit numerator and denominator.

PMID:27465203 SUPPORT Human Clinical

"Females present with mild cognitive impairment and speech difficulties."

Documents the attenuated female phenotype that contrasts with Rett syndrome.

PMID:24328834 SUPPORT Human Clinical

"We report on the first female with the A140V MECP2 mutation presenting with late onset cognitive regression, pyramidal symptoms, parkinsonism, and bipolar symptoms."

Extends the neuropsychiatric arm to heterozygous females and documents the late-onset, regressive character of the psychiatric presentation.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

18

Genitourinary 1

Macroorchidism Macroorchidism HP:0000053

Show evidence (2 references)

PMID:8651288 SUPPORT Human Clinical

"The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."

The founding description, and the only primary clinical source for the testicular phenotype in this syndrome.

PMID:20301670 SUPPORT Human Clinical

"the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability"

GeneReviews retains macroorchidism as a defining component of the PPM-X point on the male MECP2 spectrum, which is the expert-curated confirmation that the feature belongs to the entity definition.

Head and Neck 2

Microcephaly OCCASIONAL Microcephaly HP:0000252

Show evidence (1 reference)

PMID:27465203 SUPPORT Human Clinical

"Two of them show microcephaly."

Supports the association; the band is set to OCCASIONAL rather than to the literal 2/4 (50%) because microcephaly is reported in this family only and is absent from the other A140V pedigrees, so 50% would overstate it at the entity level.

Abnormal Facial Shape Abnormal facial shape HP:0001999

Severity: MILD

Show evidence (2 references)

PMID:11805248 SUPPORT Human Clinical

"Mild dysmorphic features were present in all cases."

Documents the presence of mild dysmorphism in all six affected family members.

PMID:8651288 PARTIAL Human Clinical

"The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."

Marked PARTIAL because it qualifies rather than supports the phenotype: any dysmorphism present is mild and non-specific, with no diagnostic gestalt.

Musculoskeletal 1

Spastic Paraparesis VERY_FREQUENT Spastic paraparesis HP:0002313

Course: PROGRESSIVE

Show evidence (2 references)

PMID:11805248 SUPPORT Human Clinical

"Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."

Supports the association, the VERY_FREQUENT band (6/6, 100%), and the PROGRESSIVE clinical course. Same denominator caveat as for pyramidal signs: six symptomatic relatives of one pedigree, not six of N carriers.

PMID:27465203 SUPPORT Human Clinical

"Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."

Independent replication of progressive spastic paraparesis in an unrelated family.

Nervous System 9

Intellectual Disability VERY_FREQUENT Intellectual disability HP:0001249

Show evidence (2 references)

PMID:11885030 SUPPORT Human Clinical

"This strongly suggests that A140V is a hot spot of mutation resulting in moderate to severe MR in males."

Establishes intellectual disability in the moderate-to-severe range as the constant male phenotype of the allele.

PMID:11805248 SUPPORT Human Clinical

"Mental retardation and signs of neurologic impairment were present in all the affected members, but more pronounced in men."

Supports the VERY_FREQUENT band - present in all affected members of the family - and the male-predominant severity.

Psychosis FREQUENT Psychosis HP:0000709

Show evidence (1 reference)

PMID:8651288 SUPPORT Human Clinical

"Four of the six moderately retarded males have had episodes of manic-depressive psychosis."

Supports both the association and the FREQUENT band - 4/6 affected males (66.7%) in the founding family.

Parkinsonism Parkinsonism HP:0001300

Show evidence (2 references)

PMID:8651288 SUPPORT Human Clinical

"The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."

The founding description of the extrapyramidal component.

PMID:24328834 SUPPORT Human Clinical

"One particular phenotype of parkinsonism, pyramidal signs, and neuropsychiatric symptoms (PPM-X) has been described only in males."

Confirms parkinsonism as a defining component of the entity, and states the male-restriction that the same paper then reports the first exception to.

Dystonia Dystonia HP:0001332

Show evidence (1 reference)

PMID:27465203 SUPPORT Human Clinical

"Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."

Sole primary source for the dystonic component.

Ataxia FREQUENT Ataxia HP:0001251

Show evidence (1 reference)

PMID:11805248 SUPPORT Human Clinical

"Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."

Supports the association and the FREQUENT band - 2/6 (33.3%).

Dysarthria FREQUENT Dysarthria HP:0001260

Show evidence (1 reference)

PMID:11805248 SUPPORT Human Clinical

"Speech was preserved (6/6) but was dysarthric in the oldest brothers (2/6)."

Supports the association, the FREQUENT band (2/6, 33.3%), and the preserved-speech-with-age-related-dysarthria pattern described here.

Delayed Speech and Language Development Delayed speech and language development HP:0000750

Show evidence (2 references)

PMID:27465203 SUPPORT Human Clinical

"Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."

Documents impaired language development in affected males.

PMID:27465203 SUPPORT Human Clinical

"Females present with mild cognitive impairment and speech difficulties."

Documents the corresponding, attenuated speech phenotype in carrier females.

Cognitive Impairment In Heterozygous Females Cognitive impairment HP:0100543

Severity: MILD

Show evidence (4 references)

PMID:11805248 PARTIAL Human Clinical

"The neurologic features of six symptomatic relatives (two women and four men) carrying the mutation were compiled."

Marked PARTIAL because it qualifies the phenotype rather than simply supporting it: the Siena denominators used throughout this entry are four men plus two women, and the two heterozygous women were symptomatic neurologically, not merely cognitively.

PMID:27465203 SUPPORT Human Clinical

"Females present with mild cognitive impairment and speech difficulties."

Direct description of the carrier-female phenotype.

PMID:11007980 SUPPORT Human Clinical

"We report here on a novel mutation (A140V) in the MECP2 gene detected in one female with mild mental retardation."

The index observation of the allele, made in a mildly affected heterozygous female.

+ 1 more reference

Developmental Regression Developmental regression HP:0002376

Show evidence (1 reference)

PMID:24328834 SUPPORT Human Clinical

"We report on the first female with the A140V MECP2 mutation presenting with late onset cognitive regression, pyramidal symptoms, parkinsonism, and bipolar symptoms."

Sole primary source for the regression phenotype.

Other 5

Moderate Intellectual Disability Moderate intellectual disability HP:0002342

Show evidence (2 references)

PMID:27465203 SUPPORT Human Clinical

"Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."

Documents moderate severity in the four affected males of an independently ascertained family.

PMID:8651288 SUPPORT Human Clinical

"Four of the six moderately retarded males have had episodes of manic-depressive psychosis."

The founding family is described as moderately affected, consistent with the modal severity recorded here.

Bipolar Affective Disorder Bipolar affective disorder HP:0007302

Show evidence (2 references)

PMID:24328834 SUPPORT Human Clinical

"We report on the first female with the A140V MECP2 mutation presenting with late onset cognitive regression, pyramidal symptoms, parkinsonism, and bipolar symptoms."

Documents bipolar symptomatology in an A140V carrier.

PMID:8651288 SUPPORT Human Clinical

"Four of the six moderately retarded males have had episodes of manic-depressive psychosis."

The founding description specifies the psychosis as manic-depressive, i.e. affective/bipolar in character.

Abnormal Pyramidal Sign VERY_FREQUENT Abnormal pyramidal sign HP:0007256

Show evidence (1 reference)

PMID:11805248 SUPPORT Human Clinical

"Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."

Supports the VERY_FREQUENT band - 6/6 (100%). The denominator caveat applies and is recorded in `notes:`: these six are the SYMPTOMATIC relatives of one pedigree, not all carriers, so the band describes penetrance among affected individuals rather than among carriers. The band is retained here (unlike on Distal Amyotrophy) because pyramidal signs are independently replicated in the Belgian family.

Distal Amyotrophy Distal amyotrophy HP:0003693

Show evidence (1 reference)

PMID:11805248 SUPPORT Human Clinical

"Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."

Supports the association at 6/6 within the Siena pedigree. No band is derived from it because that is the only pedigree reporting the feature.

Postural Tremor FREQUENT Postural tremor HP:0002174

Show evidence (1 reference)

PMID:11805248 SUPPORT Human Clinical

"Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."

Supports the association and the FREQUENT band - 3/6 (50%).

🧬

Genetic Associations

1

MECP2 (Causative)

Gene: MECP2 hgnc:6990 variant_origin: GERMLINE

Show evidence (5 references)

PMID:11885030 SUPPORT Human Clinical

"The A140V mutation was found in all affected males and all carrier females in the family."

Complete cosegregation of the allele with disease status in the founding PPM-X pedigree - the gene-disease validity evidence for this entry.

PMID:11007980 SUPPORT Human Clinical

"In a family study, the A140V mutation was found to segregate in the affected daughter and in four adult sons with severe mental retardation."

The index report of the Siena pedigree, supplying the original segregation observation. Note that this is the SAME family later characterised neurologically in PMID:11805248 (shared authors and institution; that paper back-references this one as "an Italian family with X-linked semidominant mental retardation"), so the two must be counted as one pedigree, not two.

PMID:11007980 SUPPORT Human Clinical

"These results indicate that MECP2 mutations are not necessarily lethal in males and that they can be causative of non-specific X-linked mental retardation."

The conceptual shift this allele forced - MECP2 lesions had until then been assumed lethal in hemizygous males.

+ 2 more references

💊

Medical Actions

4

Psychotropic Management of Psychosis and Affective Symptoms

Action: Pharmacotherapy NCIT:C15986

Agent: risperidone CHEBI:8871

The psychiatric component is the most treatable part of this syndrome and the one most likely to be missed, because it emerges in adolescence or adult life against a stable background of developmental disability. Management is symptomatic and follows general practice for affective psychosis in intellectual disability; GeneReviews notes risperidone for agitation in MECP2 disorders. There is no PPM-X-specific trial evidence and no disease-modifying therapy. One important safety constraint carries over from the MECP2 disorders literature: drugs known to prolong the QT interval should be avoided, which is directly relevant here because several antipsychotics do exactly that.

Target Phenotypes: Psychosis HP:0000709 Bipolar affective disorder HP:0007302

Show evidence (3 references)

PMID:20301670 PARTIAL Human Clinical

"Risperidone may help in treating agitation; melatonin can ameliorate sleep disturbances."

Marked PARTIAL: this is expert-consensus management guidance for MECP2 disorders as a group, directed at agitation rather than at the affective psychosis specific to PPM-X, and it is not efficacy evidence in this entity.

PMID:20301670 PARTIAL Human Clinical

"Agents/circumstances to avoid: Drugs known to prolong the QT interval."

Marked PARTIAL: this is the GeneReviews drug-safety warning for MECP2 disorders as a group, and the QTc prolongation that motivates it is documented in Rett syndrome, not in PPM-X - no cardiac phenotype has been reported in any A140V pedigree. It is carried here as a precautionary, group-level warning because antipsychotics used for the psychiatric phenotype are themselves a common source of QT prolongation, not because PPM-X is known to carry a baseline QTc risk.

PMID:8651288 SUPPORT Human Clinical

"Four of the six moderately retarded males have had episodes of manic-depressive psychosis."

Establishes the treatment indication - the affective psychosis this management is directed at.

Spasticity Management

Action: physical therapy Ontology label: Physical Therapy NCIT:C15302

The slowly progressive spastic paraparesis is the main driver of motor disability in adults and is managed per standard care for spasticity - physiotherapy, stretching and gait work, with antispastic pharmacotherapy and orthotics as required. No PPM-X-specific outcome data exist; this is recorded because spasticity is near-universal in the reported families and progressive.

Target Phenotypes: Spastic paraparesis HP:0002313

Show evidence (2 references)

PMID:20301670 PARTIAL Human Clinical

"Treatment of seizures, constipation, gastroesophageal reflux, scoliosis, prolonged QTc, and spasticity per standard care."

Marked PARTIAL: GeneReviews directs spasticity management to standard care for MECP2 disorders generally; it is not efficacy evidence in PPM-X.

PMID:11805248 SUPPORT Human Clinical

"Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."

Establishes the treatment indication and its progressive character.

Developmental and Educational Intervention

Action: speech and language therapy Ontology label: Speech Language Therapy NCIT:C159273

Management of the developmental phenotype is supportive and generic: early intervention, special education, and speech and language therapy directed at the impaired language development seen in affected males and the speech difficulties seen in carrier females. There is no disease-specific evidence base.

Target Phenotypes: Delayed speech and language development HP:0000750

Show evidence (1 reference)

PMID:27465203 PARTIAL Human Clinical

"Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."

Marked PARTIAL: this establishes the universal need for developmental and language intervention but is not evidence for the efficacy of any specific therapy in this disorder.

Genetic Counselling

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Counselling must be framed around the semidominant X-linked pattern rather than a simple recessive model, because carrier females are frequently mildly affected and can occasionally be fully symptomatic. Carrier mothers have a 50% risk of transmitting the allele to each child; sons who inherit it will be affected, daughters who inherit it may be mildly affected. Because the disorder is caused by one recurrent allele, targeted testing of at-risk relatives is straightforward once the proband is diagnosed. The reported pedigrees are multiplex three- and four-generation families, so the recurrence risk conversation is often not hypothetical.

Show evidence (2 references)

PMID:11885030 SUPPORT Human Clinical

"The A140V mutation was found in all affected males and all carrier females in the family."

Establishes the multiplex familial transmission and the existence of identifiable carrier females that the counselling model rests on.

PMID:20301670 SUPPORT Human Clinical

"When the mother is a known heterozygote, the risk to her offspring of inheriting the MECP2 variant is 50%."

The GeneReviews recurrence-risk figure for MECP2 disorders.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from PPM-X Syndrome:

Fragile X syndrome MONDO:0010383

Overlapping Features The single most important differential for this entry, and the reason the curation of this disorder requires deliberate care. Intellectual disability plus macroorchidism in a male with an X-linked family history is the classic fragile X presentation, fragile X is orders of magnitude commoner, and any literature search on "X-linked intellectual disability" plus "macroorchidism" returns overwhelmingly fragile X material. The two are nevertheless unambiguously distinct: fragile X is caused by CGG repeat expansion and methylation silencing of FMR1 at Xq27.3, PPM-X by a point mutation in MECP2 at Xq28. The founding PPM-X paper anticipated the confusion and excluded fragile X formally before naming the syndrome, testing both for cytogenetic fragile sites and for repeat expansion at FRAXA, FRAXE and FRAXF. Clinically, PPM-X adds progressive spastic paraparesis, parkinsonism and affective psychosis, and lacks the characteristic fragile X facial gestalt of a long face with prominent ears. Fragile X testing is normal in PPM-X and must not be treated as excluding this diagnosis.

Show evidence (2 references)

PMID:8651288 SUPPORT Human Clinical

"Affected males do not show fragile sites at distal Xq on cytogenetic analysis, nor do they have expansions of the CGG repeats at the FRAXA, FRAXE, or FRAXF loci."

The formal exclusion of fragile X in the founding family. This is the primary evidence that PPM-X is a separate entity from fragile X syndrome despite the shared intellectual-disability-plus-macroorchidism presentation, and it is why this disorder is curatable as a standalone dismech entry.

PMID:8651288 SUPPORT Human Clinical

"a maximal LOD score of 3.311 at theta = .0 was observed with the microsatellite marker DXS1123 in Xq28"

Independent positional evidence separating the two: the PPM-X locus maps to Xq28, whereas FMR1 is at Xq27.3.

Rett syndrome MONDO:0010726

Overlapping Features The same-gene differential. Rett syndrome and PPM-X are both MECP2 disorders but sit at opposite corners of the allele-by-sex space. Classic Rett affects females and follows a stereotyped course of normal early development, stagnation, rapid regression with loss of purposeful hand use and hand stereotypies, and acquired microcephaly; the causative MBD substitutions typically abolish methyl-CpG binding, and in hemizygous males they usually cause fatal neonatal encephalopathy. PPM-X affects males, spares methyl-CpG binding, produces no hand stereotypies and no Rett regression sequence, and leaves heterozygous females normal or only mildly affected. A140V is explicitly not a Rett allele. Evidence must never be pooled between this entry and `Rett_Syndrome`, and the Rett-specific clinical features of the shared GeneReviews chapter do not belong in this entry.

Show evidence (3 references)

PMID:17296936 SUPPORT Other

"A140V is not an RTT mutation but has been reported in hemizygous males of several independent XLMR families"

Explicit allele-level separation of PPM-X from Rett syndrome.

PMID:11007980 SUPPORT Human Clinical

"In contrast to the preponderance of affected males in families with X-linked mental retardation, Rett syndrome (RTT) is a neurological disorder occurring almost exclusively in females."

States the sex distribution that separates the two entities.

PMID:20301670 SUPPORT Human Clinical

"the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability"

The GeneReviews framing that places PPM-X and Rett syndrome as separate points on one gene's phenotypic spectrum.

Severe neonatal-onset encephalopathy with microcephaly (male MECP2 encephalopathy) MONDO:0010397

Overlapping Features The other male MECP2 phenotype, and the one that makes PPM-X surprising. Most hemizygous males with a Rett-causing MECP2 variant develop a relentless neonatal-onset encephalopathy with abnormal tone, involuntary movements, severe seizures and breathing abnormalities, and die before age two. PPM-X males survive into adulthood with moderate intellectual disability. The distinction is allelic: it is the specific separation-of-function character of p.Ala140Val, which spares methyl-CpG binding, that permits survival. A male with a MECP2 variant and a survivable, slowly progressive phenotype should prompt attention to which variant it is.

Show evidence (2 references)

PMID:20301670 SUPPORT Human Clinical

"Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities."

The GeneReviews description of the phenotype that must be distinguished from PPM-X in a male with a MECP2 variant.

PMID:11805248 SUPPORT Human Clinical

"MECP2 mutations, originally described in a high percentage of patients with classic Rett syndrome, were considered lethal in men."

States the prior expectation of male lethality that this allele violates, which is the clinical reason the two male phenotypes must be told apart.

Alpha-thalassemia X-linked intellectual disability syndrome (ATR-X) Not Yet Curated MONDO:0010519

Overlapping Features A mechanistically motivated differential rather than a purely clinical one. ATR-X syndrome is caused by mutation of ATRX itself - the very protein that MeCP2 p.Ala140Val fails to recruit - so the two disorders are predicted to converge on a shared chromatin defect approached from opposite sides of one interaction. They share intellectual disability, microcephaly, spasticity and mild dysmorphism. They are separated by the features unique to ATR-X: alpha-thalassemia, genital and urogenital anomalies, and growth deficiency, none of which are part of PPM-X. The overlap is the empirical basis of the ATRX-mislocalisation hypothesis recorded in `mechanistic_hypotheses`, and the non-overlap is why that hypothesis is at best a partial phenocopy model.

Show evidence (1 reference)

PMID:17296936 SUPPORT In Vitro

"We report that MeCP2 interacts with ATRX, a SWI2/SNF2 DNA helicase/ATPase that is mutated in ATRX syndrome (alpha-thalassemia/mental retardation, X-linked)."

Establishes the shared molecular node - ATRX - that makes this differential mechanistically interesting rather than merely phenotypically similar.

{ }

Source YAML

click to show

name: PPM-X Syndrome
creation_date: '2026-08-01T00:00:00Z'
category: Genetic
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:8651288
      reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
        pyramidal signs, and macroorchidism maps to Xq28.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."
      explanation: The core of the syndrome is a neurological phenotype - pyramidal
        and extrapyramidal signs on a background of intellectual disability.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:11885030
      reference_title: A mutation hot spot for nonspecific X-linked mental retardation
        in the MECP2 gene causes the PPM-X syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report here the genetic cause of the X-linked syndrome of psychosis, pyramidal signs, and macro-orchidism (PPM-X) in a three-generation family manifesting the disorder as a mutation in the methyl-CpG binding-protein 2 (MECP2) gene in Xq28."
      explanation: A single-gene germline aetiology supports classification as a
        genetic disease.
parents:
- Neurodevelopmental Disorder
- X-linked Disorder
- Chromatinopathy
disease_term:
  preferred_term: X-linked intellectual disability-psychosis-macroorchidism syndrome
  term:
    id: MONDO:0010235
    label: X-linked intellectual disability-psychosis-macroorchidism syndrome
synonyms:
- PPM-X
- PPM-X syndrome
- Lindsay-Burn syndrome
- MRXS13
- intellectual disability, X-linked, syndromic 13
- intellectual developmental disorder, X-linked, syndromic 13
- mental retardation with psychosis, pyramidal signs, and macroorchidism
- mental retardation, X-linked, syndromic 13
- X-linked intellectual disability with spasticity
- MECP2 p.Ala140Val-related X-linked intellectual disability
description: >
  PPM-X syndrome (MRXS13; OMIM 300055; ORPHA:3077) is a rare X-linked syndromic
  intellectual disability caused by the recurrent MECP2 missense variant
  c.419C>T p.(Ala140Val), which lies in the alpha-1 helix of the
  methyl-CpG-binding domain (MBD) at Xq28. The acronym encodes the founding
  tetrad: Psychosis, Pyramidal signs, Macroorchidism, and X-linked intellectual
  disability. It was delineated by Lindsay and colleagues in 1996 in a
  three-generation family in which four of six moderately affected males had
  episodes of manic-depressive psychosis, and was assigned to MECP2 by Klauck and
  colleagues in 2002 in that same family.

  The molecular lesion is unusually well characterised and unusually specific.
  p.Ala140Val leaves methyl-CpG binding and heterochromatic targeting of MeCP2
  intact while abolishing recruitment of the SWI/SNF-family chromatin remodeller
  ATRX to those sites. It is not the only MBD substitution that spares
  methyl-CpG binding - the Rett allele R133C does too - but it is the cleanest
  separation-of-function allele, because loss of the ATRX interaction is its only
  measurable defect, whereas R133C additionally acquires binding to
  non-methylated DNA. The allele therefore uncouples the DNA-binding and
  ATRX-binding functions of MeCP2, which is the mechanistic explanation for why it
  produces a survivable, comparatively mild, non-Rett phenotype in hemizygous
  males rather than the neonatal encephalopathy that most male MECP2 lesions cause.

  Clinically the male phenotype is a slowly progressive spastic paraparesis with
  distal leg wasting, tremor, ataxia and dysarthria layered on moderate
  intellectual disability, with parkinsonian features and adult-onset affective
  psychosis in a subset. Heterozygous females are usually normal or mildly
  affected - a further contrast with Rett syndrome, where MECP2 variants act in
  the opposite direction with respect to sex.

  Named-entity caution. PPM-X is NOT fragile X syndrome. The pairing of
  intellectual disability with macroorchidism is the fragile X clinical signature,
  and fragile X dominates any literature search on those two terms, but the
  founding PPM-X family was explicitly shown to be negative for fragile sites at
  distal Xq and for CGG expansion at FRAXA, FRAXE and FRAXF before the syndrome
  was named. The gene is MECP2, not FMR1; see the differential_diagnoses section.
references:
- reference: PMID:8651288
  title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis, pyramidal
    signs, and macroorchidism maps to Xq28.'
  findings: []
- reference: PMID:11885030
  title: A mutation hot spot for nonspecific X-linked mental retardation in the MECP2
    gene causes the PPM-X syndrome.
  findings: []
- reference: PMID:20301670
  title: MECP2 Disorders.
  tags:
  - GeneReviews
  findings: []
notes: >
  Named Entity Confusion (NEC) preflight, run 2026-08-01 before any deep-research
  content was used. MONDO:0010235 has no MONDO definition text, so the identity
  anchors used were: (1) the MONDO gene relationship `RO:0004003 HGNC:6990 !
  MECP2`; (2) the OMIM xref `OMIM:300055`, matching the OMIM number asserted in
  MedGen 163232 and quoted inside PMID:20163734 and PMID:27465203; and (3) the
  synonym list, which carries PPM-X, Lindsay-Burn syndrome and MRXS13. All three
  converge on MECP2 p.Ala140Val. The predicted NEC attractor for this entity is
  fragile X syndrome (FMR1), because intellectual disability plus macroorchidism
  is the fragile X signature; the founding paper (PMID:8651288) rules fragile X
  out explicitly and that exclusion is curated as evidence on the fragile X
  differential rather than left implicit.

  Two further NEC traps were checked and avoided. First, PMID:9222958 (Pai et al.,
  "A new X linked recessive syndrome of mental retardation and mild dysmorphism
  maps to Xq28") is returned by a PubMed search for "PPM-X syndrome" and maps to
  the same Xq28 interval, but it describes a DIFFERENT family and states that none
  of its patients had features of the PPM-X syndrome. It is deliberately not cited
  anywhere in this entry. Second, the MONDO synonym list folds in the historical
  nonsyndromic designations MRX16 and MRX79; MRX79 (PMID:12325019) is included
  here because it was shown to carry the same A140V allele. MRX16, by contrast,
  carries a DIFFERENT MECP2 allele (E137G; PMID:11309367) and was merged into
  MONDO:0010235 on nomenclatural grounds only - it is excluded from every A140V
  pedigree count in this entry, and the entity-boundary discussion says so
  explicitly.

  Deep research. One Edison/falcon run was performed
  (`research/PPM-X_Syndrome-deep-research-falcon.md`, 640 s, 20 citations). It
  passed the NEC gene-frequency check decisively (MECP2 mentioned 70 times, FMR1
  once) and its framing is sound - it explicitly separates direct PPM-X evidence
  from MECP2-spectrum and Rett evidence, and it independently confirms that no
  PPM-X-specific prevalence estimate, diagnostic guideline, biomarker or
  interventional trial exists. However it contributed no usable primary evidence
  and all three of its "key primary publications" were wrong on verification:
  (a) PMID:11951158, given as Klauck et al. AJHG 2002, is in fact a German-language
  COPD exercise-training paper in Pneumologie - a fabricated PMID attribution (the
  DOI it supplied, 10.1086/339553, is correct and resolves to PMID:11885030);
  (b) PMID:11309367 is labelled the "original syndrome report" but is Couvert et al.
  2001, "MECP2 is highly mutated in X-linked mental retardation" - the actual
  founding report is PMID:8651288 (Lindsay et al. 1996), which the report never
  cites; (c) PMID:16966553 is offered as an A140V phenotypic expansion but reports
  a different MECP2 allele (964C>T) and is not cited here. The report also missed
  the central mechanism of this disorder entirely - it speculates about
  NCoR/SMRT and states that no variant-specific mechanism is established for
  A140V, whereas the A140V-specific ATRX-recruitment defect (PMID:17296936) is well
  documented. This entry is therefore built from primary literature retrieved
  directly from PubMed, with the DR report used only as a negative control and as
  corroboration of the evidence gaps. It is retained in `research/` for
  provenance.

  GeneReviews baseline: there is no GeneReviews chapter titled for PPM-X. The
  applicable chapter is "MECP2 Disorders" (PMID:20301670, updated 2025-12-04),
  which covers PPM-X explicitly as one point on the male MECP2 spectrum and is
  tagged in the top-level `references:` block. Its Clinical Characteristics
  section is written around classic Rett syndrome in females and severe neonatal
  encephalopathy in males; the only PPM-X-specific content in the cached abstract
  is the single spectrum sentence, which is curated on the macroorchidism
  phenotype and the Rett differential. Its Management content (risperidone for
  agitation, spasticity per standard care) and its Agents-to-Avoid warning
  (QT-prolonging drugs) are carried into the treatments section. Rett-specific
  features from that chapter (hand stereotypies, apnea/hyperpnea, acquired
  microcephaly as part of classic Rett regression) are deliberately NOT curated
  here: they belong to the female Rett phenotype, not to PPM-X, and importing them
  would be exactly the kind of same-gene entity blending this entry is trying to
  avoid.

  Frequency bands. Denominators are small and come from single pedigrees, so
  several phenotypes carry no `frequency:` at all.

  CRITICAL denominator caveat, which applies to every band derived from the Siena
  family (PMID:11805248): the "/6" denominator is SIX SYMPTOMATIC RELATIVES - four
  men and two women - not six carriers and not six males. Bands derived from it
  therefore describe the distribution of features among affected individuals in
  one pedigree, not penetrance among carriers, and they are not male-specific.
  Notably, the two heterozygous women in that family shared the pyramidal signs
  and distal leg atrophy, which is why the female phenotype in this entry is
  described as milder in severity rather than restricted in system involvement.

  Bands asserted, each from an explicitly quoted count: psychosis 4/6 affected
  males in the founding Newcastle family (66.7%, FREQUENT); pyramidal signs 6/6
  and spastic paraparesis 6/6 in the Siena family (100%, VERY_FREQUENT, retained
  because both are independently replicated in the Belgian family); postural
  tremor 3/6 (50%, FREQUENT); ataxia 2/6 (33.3%, FREQUENT); dysarthria 2/6
  (33.3%, FREQUENT). Microcephaly is reported as "Two of them" among four affected
  males in the Belgian family but is absent from the other pedigrees, so it is
  recorded as OCCASIONAL rather than at the literal 50%.

  Two phenotypes are deliberately left WITHOUT a band despite having a quotable
  count. Distal amyotrophy is 6/6 in the Siena family but has never been reported
  in any other A140V pedigree, so a VERY_FREQUENT band would generalise a single
  unreplicated observation. Macroorchidism is in the syndrome name and in the
  founding description, but no A140V series reports a testicular-volume count at
  all, so no band is defensible; that gap is recorded as a KNOWLEDGE_GAP
  discussion.

  Pedigree accounting. The distinct A140V pedigrees are: Newcastle/PPM-X
  (PMID:8651288, PMID:11885030 - one family across both papers), Siena
  (PMID:11007980 and PMID:11805248 - ALSO one family across both papers; Dotti
  back-references Orrico's "Italian family with X-linked semidominant mental
  retardation", and the author lists overlap), MRX79 (PMID:12325019), and the
  Belgian four-generation family (PMID:27465203), plus sporadic cases including
  the two in PMID:11309367. Paper count must not be mistaken for pedigree count.

  Structured-source citations were NOT used. ORPHA:3077 is not present in
  `references_cache/`, and `just refresh-orphadata` fails on a checksum mismatch
  against the pinned `data/orphadata/MANIFEST.yaml` (upstream Orphadata has been
  republished since the pin). Repinning the manifest would rewrite all 328 cached
  ORPHA files and is out of scope for a curation PR. Consequently no Orphanet
  prevalence class and no Orphanet HPO frequency row is cited, and `prevalence`
  records only a literature case count.

  Deliberately out of scope: the very large Rett syndrome and MECP2 duplication
  literatures (curated in `Rett_Syndrome.yaml` and `MECP2_Duplication_Syndrome.yaml`),
  the male MECP2 severe neonatal encephalopathy phenotype (a separate MONDO
  entity, curated here only as a differential), and the general MECP2 structural
  biology literature that does not address p.Ala140Val specifically. Several
  phenotypes suggested by the deep-research report (anxiety, social withdrawal,
  rigidity, specific learning disability) are omitted because that report itself
  flags them as extrapolated from broader male MECP2 case literature rather than
  validated PPM-X features, and no A140V-specific source for them was found.
pathophysiology:
- name: MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant
  biological_scale: MOLECULAR
  description: >
    The lesion is a single recurrent missense allele, c.419C>T p.(Ala140Val), in
    the MECP2 gene at Xq28. Unlike most Mendelian entries this disorder has
    effectively an allele series of one: every reported PPM-X or A140V family
    carries the same substitution, which sits in the alpha-1 helix of the
    methyl-CpG-binding domain. It is a genuine recurrent mutation rather than a
    rare polymorphism - it segregates with the disease haplotype in multiple
    unrelated multiplex pedigrees and is enriched in male intellectual-disability
    cohorts - and it accounts for roughly 0.6% of all reported MeCP2 variants.
    Hemizygous males are affected; heterozygous females are normal or mildly
    affected.
  gene:
    preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  evidence:
  - reference: PMID:11885030
    reference_title: A mutation hot spot for nonspecific X-linked mental retardation
      in the MECP2 gene causes the PPM-X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report here the genetic cause of the X-linked syndrome of psychosis, pyramidal signs, and macro-orchidism (PPM-X) in a three-generation family manifesting the disorder as a mutation in the methyl-CpG binding-protein 2 (MECP2) gene in Xq28."
    explanation: >
      The gene-assignment paper and the strongest identity anchor for this entry:
      it binds the PPM-X acronym directly to MECP2 at Xq28, and it did so in the
      same family that Lindsay and colleagues used to define the syndrome.
  - reference: PMID:11885030
    reference_title: A mutation hot spot for nonspecific X-linked mental retardation
      in the MECP2 gene causes the PPM-X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This strongly suggests that A140V is a hot spot of mutation resulting in moderate to severe MR in males."
    explanation: Establishes A140V as a recurrent hot-spot allele rather than a
      private family variant.
  - reference: PMID:12325019
    reference_title: 'Identification of a family with nonspecific mental retardation
      (MRX79) with the A140V mutation in the MECP2 gene: is there a need for routine
      screening?'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to data published by others, this suggests that A140V is a recurrent mutation (and not a polymorphism) found in patients with X-linked mental retardation."
    explanation: >
      Independent confirmation of recurrence and, importantly, an explicit
      statement that the allele is pathogenic rather than a benign variant - the
      question that dominated the early A140V literature.
  - reference: PMID:20163734
    reference_title: Abnormalities of cell packing density and dendritic complexity
      in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "One of these mutations, A140V, is a common, recurring missense mutation accounting for about 0.6% of all MeCP2 mutations and ranking 21st by frequency."
    explanation: Sources the 0.6% allele-frequency statement in the description.
  downstream:
  - target: Selective Loss of ATRX Recruitment with Preserved Methyl-CpG Binding
    hypothesis_groups:
    - atrx_mislocalization_model
- name: Selective Loss of ATRX Recruitment with Preserved Methyl-CpG Binding
  biological_scale: MOLECULAR
  description: >
    This is the discriminating node of the entry and the reason PPM-X is
    mechanistically separable from Rett syndrome despite sharing a gene. MeCP2
    normally binds methylated CpG dinucleotides and, in a
    DNA-methylation-dependent manner, recruits ATRX - a SWI2/SNF2 helicase/ATPase
    chromatin remodeller, itself the ATR-X syndrome gene - to heterochromatic
    foci. The ATRX-interacting domain of MeCP2 overlaps the methyl-CpG-binding
    domain, and MBD point mutations causing either Rett syndrome or X-linked
    intellectual disability inhibit the ATRX interaction. What is distinctive
    about p.Ala140Val is not that it spares methyl-CpG binding - the Rett allele
    R133C does that too - but that loss of the ATRX interaction is its ONLY
    measurably altered property: it binds methylated DNA normally, targets
    heterochromatin efficiently, and, unlike R133C, does not acquire aberrant
    binding to non-methylated DNA. That makes it the cleanest natural
    separation-of-function allele in MeCP2.

    Two consequences follow. Mechanistically, the phenotype of PPM-X can be
    attributed largely to mislocalised ATRX rather than to failed methyl-CpG
    reading. Clinically, this hypomorphic, function-selective character is the
    most plausible explanation for the sex-reversed severity pattern relative to
    Rett syndrome - hemizygous males survive with moderate intellectual disability
    instead of dying of neonatal encephalopathy, while heterozygous females are
    normal or only mildly affected instead of having classic Rett syndrome.
  gene:
    preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  - preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  molecular_functions:
  - preferred_term: methyl-CpG binding
    term:
      id: GO:0008327
      label: methyl-CpG binding
  biological_processes:
  - preferred_term: heterochromatin organization
    term:
      id: GO:0070828
      label: heterochromatin organization
    modifier: ABNORMAL
  evidence:
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We report that MeCP2 interacts with ATRX, a SWI2/SNF2 DNA helicase/ATPase that is mutated in ATRX syndrome (alpha-thalassemia/mental retardation, X-linked)."
    explanation: Establishes the MeCP2-ATRX interaction that this node is built on.
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Point mutations within the methylated DNA-binding domain of MeCP2 that cause Rett syndrome or X-linked mental retardation inhibit its interaction with ATRX in vitro and its localization in vivo without affecting methyl-CpG binding."
    explanation: >
      The abstract-level statement of the separation of function: MBD point
      mutations, including the XLMR allele tested here, kill ATRX binding while
      leaving methyl-CpG binding intact.
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Neither the R133C nor the A140V mutations affected binding to methylated DNA"
    explanation: >
      Direct experimental demonstration, in the full text, that A140V specifically
      preserves methylated-DNA binding - the "preserved" half of this node.
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Specifically, the A140V and R133C mutant proteins localize efficiently to heterochromatic foci, but are unable to recruit the C terminus of ATRX to these sites."
    explanation: >
      The "selective loss" half of this node: correct targeting, failed ATRX
      recruitment.
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The A140V mutation is therefore of particular interest, because its only measurably altered property is loss of the ability to interact with ATRX."
    explanation: >
      The authors' own statement that A140V is a clean separation-of-function
      allele. This is the single most important mechanistic sentence for this
      disorder.
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The A140V phenotype is evidently less severe than that of mutations causing RTT, because heterozygous females are either normal or occasionally suffer mild mental retardation."
    explanation: >
      Links the biochemical selectivity to the clinical contrast with Rett
      syndrome, which is the sex-reversed severity claim made in this node's
      description.
  - reference: PMID:20163734
    reference_title: Abnormalities of cell packing density and dendritic complexity
      in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Interestingly, this mutation has been reported to preserve the methyl-CpG binding function of the MeCP2 protein while compromising its ability to bind to the mental retardation associated protein ATRX."
    explanation: Independent restatement of the separation of function by a
      different group.
  downstream:
  - target: Disrupted Neuronal Maturation and Dendritic Arborization
    hypothesis_groups:
    - atrx_mislocalization_model
- name: Disrupted Neuronal Maturation and Dendritic Arborization
  biological_scale: CELLULAR
  description: >
    Downstream of the chromatin lesion the affected cell type is the neuron, and
    the defect is one of maturation rather than survival. In the A140V knock-in
    mouse, cortical and hippocampal neurons are packed more densely and their
    dendritic trees are significantly less complex than wild type. Cultured
    hippocampal and cerebellar granule neurons from the same model have smaller
    somata, and this size deficit is cell-autonomous: in heterozygous females
    carrying a wild-type allele marked with eGFP, only the neurons expressing the
    mutant allele are small. The size phenotype tracks with down-regulation of
    mTOR signalling and is rescued in vitro by IGF-1.

    Note that all of the cellular evidence at this node is from the mouse
    knock-in or from cultures derived from it. No human neuropathology or
    patient-derived neuronal model of p.Ala140Val has been published, and the
    mouse is described by its makers as a Rett syndrome / XLMR model rather than a
    PPM-X model - see the HUMAN_MODEL_MISMATCH discussion.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: hippocampal pyramidal neuron
    term:
      id: CL:1001571
      label: hippocampal pyramidal neuron
  - preferred_term: cerebellar granule cell
    term:
      id: CL:0001031
      label: cerebellar granule cell
  biological_processes:
  - preferred_term: dendrite development
    term:
      id: GO:0016358
      label: dendrite development
    modifier: DECREASED
  - preferred_term: TOR signaling
    term:
      id: GO:0031929
      label: TOR signaling
    modifier: DECREASED
  evidence:
  - reference: PMID:20163734
    reference_title: Abnormalities of cell packing density and dendritic complexity
      in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The abnormalities found include increases in cell packing density in the brain and a significant reduction in the complexity of neuronal dendritic branching."
    explanation: The primary structural finding in the allele-matched mouse model.
  - reference: PMID:27781091
    reference_title: Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V
      Rett syndrome mouse model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Cultured hippocampus and cerebellar granule neurons from mutant animals were significantly smaller than neurons from wild type animals."
    explanation: >
      Establishes the reduced-soma-size cellular phenotype in two neuronal
      populations. Tagged IN_VITRO rather than MODEL_ORGANISM because the
      measurement is in primary cultures derived from the mice, not in the intact
      animal - the authors themselves call it "an important in vitro cellular
      phenotype".
  - reference: PMID:27781091
    reference_title: Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V
      Rett syndrome mouse model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the size of neurons expressing the mutant (A140V) allele also showed a significant reduction compared to neurons expressing wild type MeCP2, supporting a cell-autonomous role for MeCP2 in neuronal development"
    explanation: >
      The mosaic-female culture experiment showing the defect is cell-autonomous,
      which matters because it argues the neuronal phenotype is not a secondary
      consequence of a sick brain environment. IN_VITRO: cultured neurons from
      doubly heterozygous females.
  - reference: PMID:27781091
    reference_title: Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V
      Rett syndrome mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "mutation leads to down-regulation of the mTOR signaling pathway, known to be involved in neuronal size regulation"
    explanation: >
      Anchors the DECREASED TOR signaling annotation on this node and supplies the
      mechanistic link between the chromatin lesion and the reduced-soma-size
      phenotype.
  - reference: PMID:27781091
    reference_title: Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V
      Rett syndrome mouse model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "IGF-1 (insulin growth factor-1) treatment of neuronal cells from Mecp2 mutant mice rescued the soma size phenotype."
    explanation: >
      Pharmacological rescue in cultured neurons, which both supports the causal
      direction of this node and is the only therapeutic lead reported for the
      A140V allele. It is explicitly not evidence of clinical benefit: no IGF-1
      trial has been conducted in PPM-X, and it is therefore not curated as a
      treatment.
  downstream:
  - target: Hippocampal Network Hyperexcitability and Impaired Synaptic Plasticity
  - target: Progressive Corticospinal and Extrapyramidal Dysfunction
- name: Hippocampal Network Hyperexcitability and Impaired Synaptic Plasticity
  biological_scale: CELLULAR
  description: >
    The structural changes translate into a shifted excitation/inhibition balance
    that is age-dependent. Young A140V mice already show intrinsic
    hyperexcitability of CA1 pyramidal neurons - depolarised resting membrane
    potential, higher firing rates, broader action potentials, smaller
    afterhyperpolarisation - together with a synaptic signature pointing the same
    way: fewer spontaneous inhibitory postsynaptic currents and a higher
    probability of evoked glutamate release. Long-term potentiation at CA3-CA1
    synapses is intact at this stage. Only in aged mice does plasticity fail, with
    deficits in both short-term and long-term potentiation appearing on top of the
    persisting hyperexcitability.

    This sequence - hyperexcitability first, plasticity failure later - is the
    cellular correlate of a disorder that is not a static encephalopathy: the human
    phenotype is a slowly progressive spastic and extrapyramidal syndrome, and in
    at least one reported individual there was frank adolescent-onset regression.
  cell_types:
  - preferred_term: hippocampal pyramidal neuron
    term:
      id: CL:1001571
      label: hippocampal pyramidal neuron
  biological_processes:
  - preferred_term: modulation of chemical synaptic transmission
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
    modifier: ABNORMAL
  evidence:
  - reference: PMID:24750778
    reference_title: Electrophysiological phenotypes of MeCP2 A140V mutant mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "hippocampal CA1 pyramidal neurons exhibited more positive resting membrane potential, increased action potential (AP) firing frequency induced by injection of depolarizing current, wider AP duration, and smaller after hyperpolarization potential compared to neurons prepared from age-matched wild-type mice, suggesting a neuronal hyperexcitation"
    explanation: The intrinsic-excitability half of the node, in young mice.
  - reference: PMID:24750778
    reference_title: Electrophysiological phenotypes of MeCP2 A140V mutant mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "At the synaptic level, A140V mutant neurons exhibited a reduced frequency of spontaneous IPSCs (inhibitory postsynaptic potentials) and an enhanced probability of evoked glutamate release, both suggesting neuronal hyperexcitation."
    explanation: The synaptic half of the node - reduced inhibition plus increased
      excitatory release probability.
  - reference: PMID:24750778
    reference_title: Electrophysiological phenotypes of MeCP2 A140V mutant mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In adult mice (11- to 13-month-old), in addition to neuronal hyperexcitation, we also found significant deficits of both short-term and long-term potentiation of CA3-CA1 synapses in A140V mice compared to WT mice."
    explanation: >
      Establishes the age-dependence: plasticity failure is a late addition, not a
      developmental given. This is the evidence for the "progressive" framing of
      this node.
  downstream:
  - target: Cognitive and Neuropsychiatric Dysfunction
- name: Progressive Corticospinal and Extrapyramidal Dysfunction
  biological_scale: ORGANISM
  description: >
    The motor arm of the syndrome and the "PP" of the acronym. All six
    symptomatic relatives in the Siena A140V family - four men AND two women -
    had slowly progressive spastic paraparesis/pyramidal signs together with
    distal atrophy of the legs, with ataxia and postural hand tremor in a subset
    and dysarthria in the oldest affected brothers. That the two heterozygous
    women were also affected motorically is important: the motor syndrome is not
    male-restricted, only male-predominant in severity.
    The independently ascertained Belgian four-generation
    family reproduced the same picture - slowly progressive spastic paraparesis
    with dystonic hand movements - which is the strongest available evidence that
    the motor syndrome is an allele property and not a single-family peculiarity.
    Parkinsonian features were part of the founding description and remain in the
    syndrome definition, though they are less consistently reported in the later
    families than the pyramidal findings.
  biological_processes:
  - preferred_term: neuromuscular process controlling posture
    term:
      id: GO:0050884
      label: neuromuscular process controlling posture
    modifier: ABNORMAL
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."
    explanation: >
      The best-quantified neurological description of the A140V phenotype, and the
      source of the frequency derivations for the motor phenotypes.
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."
    explanation: >
      Independent replication of the progressive spastic paraparesis in an
      unrelated family, which is what upgrades this from a single-pedigree
      observation to an allele-level phenotype.
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."
    explanation: The founding description, and the source of the pyramidal and
      parkinsonian components of the syndrome name.
- name: Cognitive and Neuropsychiatric Dysfunction
  biological_scale: ORGANISM
  description: >
    The cognitive and psychiatric arm, and the "P" and "X" of the acronym.
    Intellectual disability is present in every reported hemizygous male and is
    typically moderate, with impaired language development; carrier females are
    normal or have mild cognitive impairment and speech difficulties. Layered on
    this is an episodic affective psychosis: four of the six affected males in the
    founding family had episodes of manic-depressive psychosis, which is the
    feature that gave the syndrome its first letter and distinguishes it from
    nonsyndromic X-linked intellectual disability.

    The psychiatric component is age-dependent rather than congenital - it emerges
    in adolescence or adult life on a background of stable developmental
    disability - and it has now been described in a heterozygous female as well,
    who presented with late-onset cognitive regression alongside pyramidal signs,
    parkinsonism and bipolar symptoms.
  biological_processes:
  - preferred_term: learning or memory
    term:
      id: GO:0007611
      label: learning or memory
    modifier: ABNORMAL
  evidence:
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four of the six moderately retarded males have had episodes of manic-depressive psychosis."
    explanation: >
      The defining psychiatric observation of the syndrome, with an explicit
      numerator and denominator.
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Females present with mild cognitive impairment and speech difficulties."
    explanation: Documents the attenuated female phenotype that contrasts with Rett
      syndrome.
  - reference: PMID:24328834
    reference_title: Adolescent onset cognitive regression and neuropsychiatric symptoms
      associated with the A140V MECP2 mutation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report on the first female with the A140V MECP2 mutation presenting with late onset cognitive regression, pyramidal symptoms, parkinsonism, and bipolar symptoms."
    explanation: >
      Extends the neuropsychiatric arm to heterozygous females and documents the
      late-onset, regressive character of the psychiatric presentation.
mechanistic_hypotheses:
- hypothesis_group_id: atrx_mislocalization_model
  hypothesis_label: ATRX mislocalisation as the proximate cause of the PPM-X phenotype
  status: EMERGING
  description: >
    The dominant mechanistic model for this disorder is that PPM-X is, at the
    chromatin level, a partial phenocopy of ATR-X syndrome produced from the MeCP2
    side of the interaction. Because p.Ala140Val leaves methyl-CpG reading and
    heterochromatic targeting intact and its only measurable defect is failure to
    recruit ATRX, the neurological consequences should follow from ATRX being in
    the wrong place rather than from loss of MeCP2 transcriptional function. The
    model is supported by biochemistry and by the observed clinical overlap
    between the two syndromes (intellectual disability, microcephaly, spasticity,
    dysmorphism), but it has not been tested directly: no study has asked whether
    restoring ATRX targeting rescues the A140V phenotype, ATRX localisation has
    not been reported in the allele-matched mouse, and the alpha-thalassemia and
    urogenital features of ATR-X syndrome are absent from PPM-X, so the phenocopy
    is at best partial.
  evidence:
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We propose that disruption of the MeCP2-ATRX interaction leads to pathological changes that contribute to mental retardation."
    explanation: >
      The authors state the hypothesis in exactly these terms, and mark it as a
      proposal rather than a demonstrated mechanism.
phenotypes:
- name: Intellectual Disability
  category: Neurologic
  description: >
    Intellectual disability is present in every reported hemizygous male and is
    the constant feature of the syndrome. Severity is typically moderate, though
    the range across the literature runs from moderate to severe, and it is
    non-progressive in itself - the progressive elements of the disorder are
    motor and psychiatric.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:11885030
    reference_title: A mutation hot spot for nonspecific X-linked mental retardation
      in the MECP2 gene causes the PPM-X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This strongly suggests that A140V is a hot spot of mutation resulting in moderate to severe MR in males."
    explanation: Establishes intellectual disability in the moderate-to-severe range
      as the constant male phenotype of the allele.
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mental retardation and signs of neurologic impairment were present in all the affected members, but more pronounced in men."
    explanation: >
      Supports the VERY_FREQUENT band - present in all affected members of the
      family - and the male-predominant severity.
- name: Moderate Intellectual Disability
  category: Neurologic
  description: >
    Curated separately from the parent term because moderate impairment is the
    modal severity in hemizygous males and is what distinguishes this entity from
    the profound impairment of male MECP2 neonatal encephalopathy at one end and
    from nonsyndromic mild X-linked intellectual disability at the other.
  phenotype_term:
    preferred_term: Moderate intellectual disability
    term:
      id: HP:0002342
      label: Moderate intellectual disability
  evidence:
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."
    explanation: Documents moderate severity in the four affected males of an
      independently ascertained family.
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four of the six moderately retarded males have had episodes of manic-depressive psychosis."
    explanation: The founding family is described as moderately affected, consistent
      with the modal severity recorded here.
- name: Psychosis
  category: Psychiatric
  description: >
    Episodic affective (manic-depressive) psychosis is the feature that names the
    syndrome and separates it from nonsyndromic X-linked intellectual disability.
    It is adult- or adolescent-onset rather than congenital, and it is not
    universal even within the founding family. It is the least consistently
    replicated component of the acronym across later A140V pedigrees, which is a
    recognised weakness of the entity definition rather than of the underlying
    observation.
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  frequency: FREQUENT
  evidence:
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four of the six moderately retarded males have had episodes of manic-depressive psychosis."
    explanation: >
      Supports both the association and the FREQUENT band - 4/6 affected males
      (66.7%) in the founding family.
- name: Bipolar Affective Disorder
  category: Psychiatric
  description: >
    The specific psychiatric syndrome reported is bipolar rather than
    schizophreniform: the founding family had manic-depressive episodes, and the
    first reported affected heterozygous female presented with bipolar symptoms.
    Curated alongside the broader Psychosis term because the affective character
    of the psychosis is clinically actionable - it points to mood stabilisation
    rather than antipsychotic monotherapy.
  phenotype_term:
    preferred_term: Bipolar affective disorder
    term:
      id: HP:0007302
      label: Bipolar affective disorder
  evidence:
  - reference: PMID:24328834
    reference_title: Adolescent onset cognitive regression and neuropsychiatric symptoms
      associated with the A140V MECP2 mutation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report on the first female with the A140V MECP2 mutation presenting with late onset cognitive regression, pyramidal symptoms, parkinsonism, and bipolar symptoms."
    explanation: Documents bipolar symptomatology in an A140V carrier.
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four of the six moderately retarded males have had episodes of manic-depressive psychosis."
    explanation: The founding description specifies the psychosis as
      manic-depressive, i.e. affective/bipolar in character.
- name: Macroorchidism
  category: Genitourinary
  description: >
    Enlarged testes in affected males, the "M" of the acronym. This is the feature
    that creates the fragile X confusion, and it is also the least well documented
    component of the syndrome: it appears in the founding description and in the
    syndrome name, but no subsequent A140V family report gives testicular volumes
    or a count of affected males with macroorchidism, and no mechanism has been
    proposed. No frequency band is asserted for that reason, and the open question
    is recorded as a knowledge gap.
  phenotype_term:
    preferred_term: Macroorchidism
    term:
      id: HP:0000053
      label: Macroorchidism
  evidence:
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."
    explanation: The founding description, and the only primary clinical source for
      the testicular phenotype in this syndrome.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability"
    explanation: >
      GeneReviews retains macroorchidism as a defining component of the PPM-X point
      on the male MECP2 spectrum, which is the expert-curated confirmation that the
      feature belongs to the entity definition.
- name: Abnormal Pyramidal Sign
  category: Neurologic
  description: >
    Corticospinal tract signs are the most consistently replicated neurological
    feature of the A140V allele, present in every affected member of the Siena
    family and reproduced in the Belgian family. Together with the intellectual
    disability they form the stable core of the phenotype.
  phenotype_term:
    preferred_term: Abnormal pyramidal sign
    term:
      id: HP:0007256
      label: Abnormal pyramidal sign
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."
    explanation: >
      Supports the VERY_FREQUENT band - 6/6 (100%). The denominator caveat applies
      and is recorded in `notes:`: these six are the SYMPTOMATIC relatives of one
      pedigree, not all carriers, so the band describes penetrance among affected
      individuals rather than among carriers. The band is retained here (unlike on
      Distal Amyotrophy) because pyramidal signs are independently replicated in
      the Belgian family.
- name: Spastic Paraparesis
  category: Neurologic
  description: >
    A slowly progressive spastic paraparesis is the dominant motor disability in
    adults with this disorder, and its progressive character is what makes the
    entity a slowly evolving neurological disease rather than a static
    encephalopathy. It has been documented in two independently ascertained A140V
    families and is prominent enough that one of them was titled around
    intellectual disability with spasticity.
  phenotype_term:
    preferred_term: Spastic paraparesis
    term:
      id: HP:0002313
      label: Spastic paraparesis
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."
    explanation: >
      Supports the association, the VERY_FREQUENT band (6/6, 100%), and the
      PROGRESSIVE clinical course. Same denominator caveat as for pyramidal signs:
      six symptomatic relatives of one pedigree, not six of N carriers.
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."
    explanation: Independent replication of progressive spastic paraparesis in an
      unrelated family.
- name: Parkinsonism
  category: Neurologic
  description: >
    Extrapyramidal features were part of the founding description and are retained
    in the GeneReviews characterisation of PPM-X, but they are reported less
    consistently in the later A140V pedigrees than the pyramidal signs. The one
    reported affected heterozygous female also had parkinsonism. No frequency band
    is asserted because no source gives a count.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."
    explanation: The founding description of the extrapyramidal component.
  - reference: PMID:24328834
    reference_title: Adolescent onset cognitive regression and neuropsychiatric symptoms
      associated with the A140V MECP2 mutation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One particular phenotype of parkinsonism, pyramidal signs, and neuropsychiatric symptoms (PPM-X) has been described only in males."
    explanation: >
      Confirms parkinsonism as a defining component of the entity, and states the
      male-restriction that the same paper then reports the first exception to.
- name: Distal Amyotrophy
  category: Neurologic
  description: >
    Distal wasting of the legs accompanied the spastic paraparesis in all six
    symptomatic relatives of the Siena family. Its presence alongside upper motor
    neuron signs gives the motor syndrome a mixed upper/lower motor neuron
    character that is clinically distinctive. No frequency band is asserted: the
    6/6 count comes from a single pedigree and has never been replicated in
    another A140V family, so it cannot be generalised to the entity.
  phenotype_term:
    preferred_term: Distal amyotrophy
    term:
      id: HP:0003693
      label: Distal amyotrophy
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."
    explanation: >
      Supports the association at 6/6 within the Siena pedigree. No band is
      derived from it because that is the only pedigree reporting the feature.
- name: Postural Tremor
  category: Neurologic
  description: >
    Postural tremor of the hands, present in half of the affected members of the
    Siena family. Part of the movement-disorder component of the syndrome
    alongside the dystonic hand movements reported in the Belgian family.
  phenotype_term:
    preferred_term: Postural tremor
    term:
      id: HP:0002174
      label: Postural tremor
  frequency: FREQUENT
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."
    explanation: Supports the association and the FREQUENT band - 3/6 (50%).
- name: Dystonia
  category: Neurologic
  description: >
    Dystonic movements of the hands in the affected males of the Belgian
    four-generation family. Reported in that family only, so no frequency band is
    asserted.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."
    explanation: Sole primary source for the dystonic component.
- name: Ataxia
  category: Neurologic
  description: >
    Ataxia in a minority of affected individuals, adding a cerebellar element to
    the otherwise pyramidal/extrapyramidal motor picture. The 2/6 denominator is
    the Siena series of symptomatic relatives, which comprised four men and two
    women, so this is not a male-only count.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  frequency: FREQUENT
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."
    explanation: Supports the association and the FREQUENT band - 2/6 (33.3%).
- name: Dysarthria
  category: Neurologic
  description: >
    Speech is preserved in this disorder - a notable contrast with Rett syndrome -
    but becomes dysarthric with age. In the Siena family all six affected members
    had preserved speech while the two oldest brothers were dysarthric, which is
    another instance of the age-dependent progression that characterises the
    entity.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  frequency: FREQUENT
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Speech was preserved (6/6) but was dysarthric in the oldest brothers (2/6)."
    explanation: >
      Supports the association, the FREQUENT band (2/6, 33.3%), and the
      preserved-speech-with-age-related-dysarthria pattern described here.
- name: Delayed Speech and Language Development
  category: Neurologic
  description: >
    Impaired language development in affected males, and speech difficulties in
    carrier females. Distinct from the acquired dysarthria above: this is a
    developmental delay in acquiring language rather than a degradation of
    articulation.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."
    explanation: Documents impaired language development in affected males.
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Females present with mild cognitive impairment and speech difficulties."
    explanation: Documents the corresponding, attenuated speech phenotype in carrier
      females.
- name: Microcephaly
  category: Craniofacial
  description: >
    Microcephaly in a subset of affected males. Reported in only one family (two of
    four affected males), so it is recorded as occasional rather than as a
    consistent feature. It should not be conflated with the acquired microcephaly
    of classic Rett syndrome, which is part of a regression sequence not seen here.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two of them show microcephaly."
    explanation: >
      Supports the association; the band is set to OCCASIONAL rather than to the
      literal 2/4 (50%) because microcephaly is reported in this family only and is
      absent from the other A140V pedigrees, so 50% would overstate it at the
      entity level.
- name: Cognitive Impairment In Heterozygous Females
  category: Neurologic
  description: >
    Heterozygous females are usually normal or mildly affected, with mild cognitive
    impairment and speech difficulties. This is the diagnostically important
    inversion relative to Rett syndrome, where MECP2 variants produce a severe
    female phenotype, and it is the reason A140V pedigrees present as X-linked
    semidominant intellectual disability rather than as Rett families.

    "Mildly affected" should not be read as "cognitively affected only". The
    female range is wider than the modal description: two of the six symptomatic
    relatives in the Siena pedigree were women, and they shared the pyramidal
    signs and distal leg atrophy of their affected male relatives, while a
    separately reported heterozygous female developed the full neuropsychiatric
    picture with adolescent regression, parkinsonism and bipolar symptoms. What is
    consistently milder in females is severity, not the range of systems involved.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
    severity: MILD
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The neurologic features of six symptomatic relatives (two women and four men) carrying the mutation were compiled."
    explanation: >
      Marked PARTIAL because it qualifies the phenotype rather than simply
      supporting it: the Siena denominators used throughout this entry are four
      men plus two women, and the two heterozygous women were symptomatic
      neurologically, not merely cognitively.
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Females present with mild cognitive impairment and speech difficulties."
    explanation: Direct description of the carrier-female phenotype.
  - reference: PMID:11007980
    reference_title: MECP2 mutation in male patients with non-specific X-linked mental
      retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report here on a novel mutation (A140V) in the MECP2 gene detected in one female with mild mental retardation."
    explanation: The index observation of the allele, made in a mildly affected
      heterozygous female.
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The A140V phenotype is evidently less severe than that of mutations causing RTT, because heterozygous females are either normal or occasionally suffer mild mental retardation."
    explanation: States the attenuated-female pattern explicitly and contrasts it
      with Rett syndrome.
- name: Developmental Regression
  category: Neurologic
  description: >
    Late-onset cognitive regression, reported in the first described affected
    heterozygous female, who regressed in adolescence alongside emerging pyramidal
    signs, parkinsonism and bipolar symptoms. A single case, so no frequency is
    asserted, but it is curated because it is the clearest human evidence that the
    disorder has a progressive as well as a developmental component.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:24328834
    reference_title: Adolescent onset cognitive regression and neuropsychiatric symptoms
      associated with the A140V MECP2 mutation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report on the first female with the A140V MECP2 mutation presenting with late onset cognitive regression, pyramidal symptoms, parkinsonism, and bipolar symptoms."
    explanation: Sole primary source for the regression phenotype.
- name: Abnormal Facial Shape
  category: Craniofacial
  description: >
    Mild, non-specific dysmorphism. This entry is curated chiefly for its negative
    content: the founding paper states explicitly that there are no characteristic
    dysmorphic facial features, and the Siena family had only mild dysmorphism.
    There is no recognisable facial gestalt for this syndrome, which is why the
    diagnosis is molecular rather than clinical.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
    severity: MILD
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mild dysmorphic features were present in all cases."
    explanation: Documents the presence of mild dysmorphism in all six affected
      family members.
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."
    explanation: >
      Marked PARTIAL because it qualifies rather than supports the phenotype: any
      dysmorphism present is mild and non-specific, with no diagnostic gestalt.
genetic:
- name: MECP2
  association: Causative
  variant_origin: GERMLINE
  gene_term:
    preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  notes: >
    MECP2 (Xq28) encodes methyl-CpG-binding protein 2, a methylated-DNA reader
    that couples DNA methylation to chromatin state, in part by recruiting the
    SWI2/SNF2 remodeller ATRX to methylated heterochromatin. For this entity the
    allele spectrum is a single recurrent missense substitution, c.419C>T
    p.(Ala140Val), in the alpha-1 helix of the methyl-CpG-binding domain.

    Scope caution. MECP2 is a highly pleiotropic disease gene and this is only one
    of several distinct MECP2 entities curated in dismech - Rett syndrome
    (`Rett_Syndrome`), MECP2 duplication syndrome (`MECP2_Duplication_Syndrome`),
    and X-linked autism susceptibility 3 (`Autism_Susceptibility_to_X-Linked_3`).
    Evidence must not be pooled across them. In particular the mechanism of PPM-X
    is a loss of a specific protein-protein interaction, whereas Rett-causing MBD
    substitutions typically abolish methyl-CpG binding itself and duplication
    syndrome is a dosage-gain mechanism. Screening studies also matter for scope:
    A140V is recurrent in male intellectual-disability pedigrees but was not found
    at all in a Brazilian series of 363 males ascertained for intellectual
    disability or psychiatric disease, so it is a recurrent but numerically minor
    cause of X-linked intellectual disability.
  evidence:
  - reference: PMID:11885030
    reference_title: A mutation hot spot for nonspecific X-linked mental retardation
      in the MECP2 gene causes the PPM-X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The A140V mutation was found in all affected males and all carrier females in the family."
    explanation: >
      Complete cosegregation of the allele with disease status in the founding
      PPM-X pedigree - the gene-disease validity evidence for this entry.
  - reference: PMID:11007980
    reference_title: MECP2 mutation in male patients with non-specific X-linked mental
      retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a family study, the A140V mutation was found to segregate in the affected daughter and in four adult sons with severe mental retardation."
    explanation: >
      The index report of the Siena pedigree, supplying the original segregation
      observation. Note that this is the SAME family later characterised
      neurologically in PMID:11805248 (shared authors and institution; that paper
      back-references this one as "an Italian family with X-linked semidominant
      mental retardation"), so the two must be counted as one pedigree, not two.
  - reference: PMID:11007980
    reference_title: MECP2 mutation in male patients with non-specific X-linked mental
      retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results indicate that MECP2 mutations are not necessarily lethal in males and that they can be causative of non-specific X-linked mental retardation."
    explanation: >
      The conceptual shift this allele forced - MECP2 lesions had until then been
      assumed lethal in hemizygous males.
  - reference: PMID:11309367
    reference_title: MECP2 is highly mutated in X-linked mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we screened MECP2 in a cohort of 185 patients found negative for the expansions across the FRAXA CGG repeat and reported the identification of mutations in four sporadic cases of MR. One of the mutations, A140V, which we found in two patients, has been described previously"
    explanation: >
      Places the allele in its cohort-screening context and supplies the two
      sporadic A140V cases counted in the prevalence derivation. The cohort was
      explicitly fragile-X-negative, which is a second, independent line of
      evidence that A140V disease is not fragile X.
  - reference: PMID:15814190
    reference_title: The A140V mutation in the MECP2 gene is not a common etiological
      factor among Brazilian mentally retarded males.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "DNA samples from 363 male individuals with syndromic and non-syndromic mental retardation and other psychiatric diseases were screened for A140V (419C>T) mutation in the MECP2 gene, considered the most frequent MECP2 mutation in males. No 419C>T was found suggesting that the A140V mutation in the MECP2 gene is not a common cause of mental retardation in males."
    explanation: >
      Marked PARTIAL because it is a negative screening result: it does not refute
      pathogenicity of the allele in the reported families, but it bounds the
      claim, showing that A140V explains none of 363 Brazilian males ascertained
      for intellectual disability or psychiatric disease and is therefore not a
      numerically important cause in an unenriched clinical cohort.
variants:
- name: MECP2 c.419C>T p.(Ala140Val)
  description: >
    The single recurrent allele of this disorder. It substitutes valine for
    alanine at codon 140, in the alpha-1 helix of the methyl-CpG-binding domain,
    within a region where the MBD and the ATRX-interacting domain overlap. It is
    the defining separation-of-function allele of MeCP2: methylated-DNA binding
    and heterochromatic targeting are preserved, ATRX recruitment is lost. It has
    been reported in multiple unrelated multiplex X-linked pedigrees (the
    Newcastle PPM-X family, the Siena family, MRX79, and a Belgian
    four-generation family) as well as in sporadic males, and it accounts for
    approximately 0.6% of all reported MeCP2 variants. It is not a Rett syndrome
    allele.
  gene:
    preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  type: MISSENSE
  evidence:
  - reference: PMID:11885030
    reference_title: A mutation hot spot for nonspecific X-linked mental retardation
      in the MECP2 gene causes the PPM-X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The A140V mutation was found in all affected males and all carrier females in the family."
    explanation: Identifies the allele and its complete cosegregation in the PPM-X
      family.
  - reference: PMID:11885030
    reference_title: A mutation hot spot for nonspecific X-linked mental retardation
      in the MECP2 gene causes the PPM-X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, descriptions have been published of two patients with independent familial mental retardation (MR) and two patients with sporadic MR who harbor this specific mutation in the MECP2 gene."
    explanation: Documents recurrence across familial and sporadic cases at the time
      of gene assignment.
  - reference: PMID:12325019
    reference_title: 'Identification of a family with nonspecific mental retardation
      (MRX79) with the A140V mutation in the MECP2 gene: is there a need for routine
      screening?'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We mapped a new non-syndromic X-linked family (MRX79) to the chromosomal region Xq27.3-Xq28 and identified an A140V mutation in the MEPC2 gene in all patients with the disease haplotype."
    explanation: >
      Cosegregation with the disease haplotype in a fourth family, and the basis on
      which the historical MRX79 designation was merged into this entity. (The
      abstract contains the typographical error "MEPC2"; it is quoted verbatim.)
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The p.Ala140Val mutation is recurrent, as it was already described in 4 families with X-linked mental retardation and in three sporadic male patients with intellectual disability."
    explanation: Tallies the reported recurrence of the allele up to 2016.
  - reference: PMID:20163734
    reference_title: Abnormalities of cell packing density and dendritic complexity
      in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "located in the a1 helix of the MBD"
    explanation: >
      Sources the structural localisation of the substitution to the alpha-1 helix
      of the methyl-CpG-binding domain. Tagged OTHER because the statement is a
      structural/literature summary in the discussion of that paper rather than an
      experimental result of it.
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A140V is not an RTT mutation but has been reported in hemizygous males of several independent XLMR families"
    explanation: >
      Explicit statement that this is not a Rett allele, which is the key
      allele-level boundary between this entry and Rett_Syndrome.
inheritance:
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  description: >
    The pattern is X-linked but is best described as semidominant rather than
    cleanly recessive or dominant, and the sources genuinely disagree on the
    label. Hemizygous males are consistently and more severely affected; carrier
    females are frequently not normal but mildly affected, with mild cognitive
    impairment and speech difficulties, and at least one heterozygous female has
    developed the full neuropsychiatric picture with regression, pyramidal signs
    and parkinsonism. Dotti and colleagues therefore described the index family as
    X-linked semidominant. OMIM/MedGen annotate MONDO:0010235 as X-linked dominant,
    while the MONDO synonym list also carries an X-linked recessive designation
    inherited from the MRXS13 nomenclature. The generic HP:0001417 term is used
    here deliberately rather than forcing a choice between HP:0001419 and
    HP:0001423, with the semidominant reality described in prose. Expressivity is
    recorded as VARIABLE on the strength of the explicit intrafamilial variability
    reported in the Belgian family, and penetrance as INCOMPLETE because carrier
    females range from unaffected to fully symptomatic.
  evidence:
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The authors recently described a novel A140V MECP2 missense mutation in an Italian family with X-linked semidominant mental retardation."
    explanation: The explicit semidominant characterisation that this block is built
      on.
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The neurologic disorder associated with A140V MECP2 mutation is not necessarily lethal in men, but they are more severely affected than women of the same family."
    explanation: >
      Establishes the sex-severity gradient within a single pedigree, the core
      empirical observation the inheritance model rests on.
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We further delineate the phenotype associated with the p.Ala140Val mutation, illustrating a variable expressivity even within a given family"
    explanation: Direct support for the VARIABLE expressivity annotation.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 disorders are inherited in an X-linked manner."
    explanation: The GeneReviews inheritance statement for the MECP2 disorder group
      that PPM-X belongs to.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No population prevalence or incidence estimate has been published for PPM-X,
    so only a literature case count is recorded and no rate is asserted. As of the
    2016 review of the allele, p.Ala140Val had been reported in four families with
    X-linked intellectual disability plus three sporadic males, to which that
    report added a four-generation Belgian family with seven carriers (4 males, 3
    females). The one usable population-level number is not a disease rate but an
    allele share: A140V accounts for approximately 0.6% of all reported MeCP2
    variants, ranking 21st by frequency. The Orphanet prevalence class for
    ORPHA:3077 could not be cited because that record is not present in
    `references_cache/` and refreshing Orphadata currently fails on a MANIFEST
    checksum mismatch.
  evidence:
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The p.Ala140Val mutation is recurrent, as it was already described in 4 families with X-linked mental retardation and in three sporadic male patients with intellectual disability."
    explanation: Supplies the pre-2016 case tally used in the derivation.
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we report on the identification of the p.Ala140Val mutation in the MECP2 gene in 4 males and 3 females of a large Caucasian family affected with X-linked intellectual disability."
    explanation: Supplies the additional seven carriers added by that report.
  - reference: PMID:20163734
    reference_title: Abnormalities of cell packing density and dendritic complexity
      in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "One of these mutations, A140V, is a common, recurring missense mutation accounting for about 0.6% of all MeCP2 mutations and ranking 21st by frequency."
    explanation: Supplies the allele-share figure, which is the only quantitative
      population-level statement available for this entity.
diagnosis:
- name: MECP2 Sequencing
  description: >
    There is no clinical gestalt for this disorder - there are no characteristic
    dysmorphic facial features - so the diagnosis is molecular. Targeted MECP2
    sequencing, an X-linked intellectual disability gene panel, or exome/genome
    sequencing is the appropriate route in a male with unexplained intellectual
    disability plus spastic paraparesis, particularly with an X-linked family
    history. Because the entity is a single recurrent allele, targeted A140V
    testing is unusually informative: the gene-assignment paper reported a simple
    PCR prescreen for exactly this purpose. The same testing should be considered
    in females with non-classic Rett phenotypes and intellectual disability with
    neuropsychiatric features.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:11885030
    reference_title: A mutation hot spot for nonspecific X-linked mental retardation
      in the MECP2 gene causes the PPM-X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A simple and reliable PCR approach has been developed for detection of the hot spot A140V mutation to prescreen any other unexplained cases of MR before further extensive mutation analyses."
    explanation: Direct support for targeted A140V prescreening as a diagnostic
      strategy in unexplained intellectual disability.
  - reference: PMID:24328834
    reference_title: Adolescent onset cognitive regression and neuropsychiatric symptoms
      associated with the A140V MECP2 mutation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This finding emphasizes the need to consider MECP2 sequencing in females with non-classic Rett phenotypes, particularly those with intellectual disability and neuropsychiatric features."
    explanation: Extends the testing indication to symptomatic heterozygous females.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of a MECP2 disorder is established by molecular genetic testing in a female proband with suggestive findings and a heterozygous MECP2 pathogenic variant, and in a male proband with suggestive findings and a hemizygous MECP2 pathogenic variant."
    explanation: The GeneReviews diagnostic standard for the MECP2 disorder group.
- name: Multidisciplinary Surveillance Including QTc Monitoring
  description: >
    GeneReviews recommends periodic multidisciplinary review with regular QTc and
    scoliosis assessment across MECP2 disorders. This is included here for one
    specific, practical reason: the psychiatric phenotype of PPM-X is treated with
    antipsychotics, many of which prolong the QT interval, and the same chapter
    lists QT-prolonging drugs among the agents to avoid. It is group-level rather
    than PPM-X-specific guidance - no cardiac or scoliosis phenotype has been
    reported in any A140V pedigree - so it is a precaution attached to the
    treatment, not evidence of an intrinsic cardiac risk in this entity.
  diagnosis_term:
    preferred_term: electrocardiography
    term:
      id: NCIT:C38053
      label: Electrocardiography
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Surveillance: Periodic evaluation by the multidisciplinary team; regular assessment of QTc for evidence of prolongation; regular assessment for scoliosis."
    explanation: >
      Marked PARTIAL: GeneReviews surveillance guidance for MECP2 disorders as a
      group; the QTc recommendation derives from Rett syndrome data, not from
      PPM-X.
differential_diagnoses:
- name: Fragile X syndrome
  disease_term:
    preferred_term: fragile X syndrome
    term:
      id: MONDO:0010383
      label: fragile X syndrome
  description: >
    The single most important differential for this entry, and the reason the
    curation of this disorder requires deliberate care. Intellectual disability
    plus macroorchidism in a male with an X-linked family history is the classic
    fragile X presentation, fragile X is orders of magnitude commoner, and any
    literature search on "X-linked intellectual disability" plus "macroorchidism"
    returns overwhelmingly fragile X material. The two are nevertheless
    unambiguously distinct: fragile X is caused by CGG repeat expansion and
    methylation silencing of FMR1 at Xq27.3, PPM-X by a point mutation in MECP2 at
    Xq28. The founding PPM-X paper anticipated the confusion and excluded fragile X
    formally before naming the syndrome, testing both for cytogenetic fragile sites
    and for repeat expansion at FRAXA, FRAXE and FRAXF. Clinically, PPM-X adds
    progressive spastic paraparesis, parkinsonism and affective psychosis, and
    lacks the characteristic fragile X facial gestalt of a long face with prominent
    ears. Fragile X testing is normal in PPM-X and must not be treated as
    excluding this diagnosis.
  evidence:
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected males do not show fragile sites at distal Xq on cytogenetic analysis, nor do they have expansions of the CGG repeats at the FRAXA, FRAXE, or FRAXF loci."
    explanation: >
      The formal exclusion of fragile X in the founding family. This is the primary
      evidence that PPM-X is a separate entity from fragile X syndrome despite the
      shared intellectual-disability-plus-macroorchidism presentation, and it is
      why this disorder is curatable as a standalone dismech entry.
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a maximal LOD score of 3.311 at theta = .0 was observed with the microsatellite marker DXS1123 in Xq28"
    explanation: >
      Independent positional evidence separating the two: the PPM-X locus maps to
      Xq28, whereas FMR1 is at Xq27.3.
- name: Rett syndrome
  disease_term:
    preferred_term: Rett syndrome
    term:
      id: MONDO:0010726
      label: Rett syndrome
  description: >
    The same-gene differential. Rett syndrome and PPM-X are both MECP2 disorders
    but sit at opposite corners of the allele-by-sex space. Classic Rett affects
    females and follows a stereotyped course of normal early development,
    stagnation, rapid regression with loss of purposeful hand use and hand
    stereotypies, and acquired microcephaly; the causative MBD substitutions
    typically abolish methyl-CpG binding, and in hemizygous males they usually
    cause fatal neonatal encephalopathy. PPM-X affects males, spares methyl-CpG
    binding, produces no hand stereotypies and no Rett regression sequence, and
    leaves heterozygous females normal or only mildly affected. A140V is explicitly
    not a Rett allele. Evidence must never be pooled between this entry and
    `Rett_Syndrome`, and the Rett-specific clinical features of the shared
    GeneReviews chapter do not belong in this entry.
  evidence:
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A140V is not an RTT mutation but has been reported in hemizygous males of several independent XLMR families"
    explanation: Explicit allele-level separation of PPM-X from Rett syndrome.
  - reference: PMID:11007980
    reference_title: MECP2 mutation in male patients with non-specific X-linked mental
      retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In contrast to the preponderance of affected males in families with X-linked mental retardation, Rett syndrome (RTT) is a neurological disorder occurring almost exclusively in females."
    explanation: States the sex distribution that separates the two entities.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability"
    explanation: >
      The GeneReviews framing that places PPM-X and Rett syndrome as separate points
      on one gene's phenotypic spectrum.
- name: Severe neonatal-onset encephalopathy with microcephaly (male MECP2 encephalopathy)
  disease_term:
    preferred_term: severe neonatal-onset encephalopathy with microcephaly
    term:
      id: MONDO:0010397
      label: severe neonatal-onset encephalopathy with microcephaly
  description: >
    The other male MECP2 phenotype, and the one that makes PPM-X surprising. Most
    hemizygous males with a Rett-causing MECP2 variant develop a relentless
    neonatal-onset encephalopathy with abnormal tone, involuntary movements, severe
    seizures and breathing abnormalities, and die before age two. PPM-X males
    survive into adulthood with moderate intellectual disability. The distinction
    is allelic: it is the specific separation-of-function character of
    p.Ala140Val, which spares methyl-CpG binding, that permits survival. A male
    with a MECP2 variant and a survivable, slowly progressive phenotype should
    prompt attention to which variant it is.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities."
    explanation: The GeneReviews description of the phenotype that must be
      distinguished from PPM-X in a male with a MECP2 variant.
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mutations, originally described in a high percentage of patients with classic Rett syndrome, were considered lethal in men."
    explanation: >
      States the prior expectation of male lethality that this allele violates,
      which is the clinical reason the two male phenotypes must be told apart.
- name: Alpha-thalassemia X-linked intellectual disability syndrome (ATR-X)
  disease_term:
    preferred_term: alpha thalassemia-X-linked intellectual disability syndrome
    term:
      id: MONDO:0010519
      label: alpha thalassemia-X-linked intellectual disability syndrome
  description: >
    A mechanistically motivated differential rather than a purely clinical one.
    ATR-X syndrome is caused by mutation of ATRX itself - the very protein that
    MeCP2 p.Ala140Val fails to recruit - so the two disorders are predicted to
    converge on a shared chromatin defect approached from opposite sides of one
    interaction. They share intellectual disability, microcephaly, spasticity and
    mild dysmorphism. They are separated by the features unique to ATR-X:
    alpha-thalassemia, genital and urogenital anomalies, and growth deficiency,
    none of which are part of PPM-X. The overlap is the empirical basis of the
    ATRX-mislocalisation hypothesis recorded in `mechanistic_hypotheses`, and the
    non-overlap is why that hypothesis is at best a partial phenocopy model.
  evidence:
  - reference: PMID:17296936
    reference_title: Interaction between chromatin proteins MECP2 and ATRX is disrupted
      by mutations that cause inherited mental retardation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We report that MeCP2 interacts with ATRX, a SWI2/SNF2 DNA helicase/ATPase that is mutated in ATRX syndrome (alpha-thalassemia/mental retardation, X-linked)."
    explanation: >
      Establishes the shared molecular node - ATRX - that makes this differential
      mechanistically interesting rather than merely phenotypically similar.
treatments:
- name: Psychotropic Management of Psychosis and Affective Symptoms
  description: >
    The psychiatric component is the most treatable part of this syndrome and the
    one most likely to be missed, because it emerges in adolescence or adult life
    against a stable background of developmental disability. Management is
    symptomatic and follows general practice for affective psychosis in
    intellectual disability; GeneReviews notes risperidone for agitation in MECP2
    disorders. There is no PPM-X-specific trial evidence and no disease-modifying
    therapy. One important safety constraint carries over from the MECP2 disorders
    literature: drugs known to prolong the QT interval should be avoided, which is
    directly relevant here because several antipsychotics do exactly that.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: risperidone
      term:
        id: CHEBI:8871
        label: risperidone
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  - preferred_term: Bipolar affective disorder
    term:
      id: HP:0007302
      label: Bipolar affective disorder
  notes: >
    Deliberate mismatch flagged for future curation: the only agent with a
    citable source in this disorder group is an antipsychotic (risperidone, from
    GeneReviews, and directed at agitation), whereas the psychiatric phenotype
    actually reported in PPM-X is manic-depressive, which would ordinarily call
    for mood stabilisation. No mood stabiliser has been reported in any A140V
    pedigree, so none is curated here rather than inventing one; both psychosis
    and bipolar affective disorder are listed as target phenotypes to make the
    gap visible.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Risperidone may help in treating agitation; melatonin can ameliorate sleep disturbances."
    explanation: >
      Marked PARTIAL: this is expert-consensus management guidance for MECP2
      disorders as a group, directed at agitation rather than at the affective
      psychosis specific to PPM-X, and it is not efficacy evidence in this entity.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Agents/circumstances to avoid: Drugs known to prolong the QT interval."
    explanation: >
      Marked PARTIAL: this is the GeneReviews drug-safety warning for MECP2
      disorders as a group, and the QTc prolongation that motivates it is
      documented in Rett syndrome, not in PPM-X - no cardiac phenotype has been
      reported in any A140V pedigree. It is carried here as a precautionary,
      group-level warning because antipsychotics used for the psychiatric
      phenotype are themselves a common source of QT prolongation, not because
      PPM-X is known to carry a baseline QTc risk.
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four of the six moderately retarded males have had episodes of manic-depressive psychosis."
    explanation: Establishes the treatment indication - the affective psychosis this
      management is directed at.
- name: Spasticity Management
  description: >
    The slowly progressive spastic paraparesis is the main driver of motor
    disability in adults and is managed per standard care for spasticity -
    physiotherapy, stretching and gait work, with antispastic pharmacotherapy and
    orthotics as required. No PPM-X-specific outcome data exist; this is recorded
    because spasticity is near-universal in the reported families and progressive.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  therapeutic_modality: BEHAVIORAL
  target_phenotypes:
  - preferred_term: Spastic paraparesis
    term:
      id: HP:0002313
      label: Spastic paraparesis
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of seizures, constipation, gastroesophageal reflux, scoliosis, prolonged QTc, and spasticity per standard care."
    explanation: >
      Marked PARTIAL: GeneReviews directs spasticity management to standard care
      for MECP2 disorders generally; it is not efficacy evidence in PPM-X.
  - reference: PMID:11805248
    reference_title: A Rett syndrome MECP2 mutation that causes mental retardation in
      men.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features included slowly progressive spastic paraparesis/pyramidal signs (6/6), distal atrophy of the legs (6/6), ataxia (2/6), and postural tremor of the hands (3/6)."
    explanation: Establishes the treatment indication and its progressive character.
- name: Developmental and Educational Intervention
  description: >
    Management of the developmental phenotype is supportive and generic: early
    intervention, special education, and speech and language therapy directed at
    the impaired language development seen in affected males and the speech
    difficulties seen in carrier females. There is no disease-specific evidence
    base.
  treatment_term:
    preferred_term: speech and language therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  therapeutic_modality: BEHAVIORAL
  target_phenotypes:
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Males have moderate intellectual disability, impaired language development, friendly behavior, slowly progressive spastic paraparesis and dystonic movements of the hands."
    explanation: >
      Marked PARTIAL: this establishes the universal need for developmental and
      language intervention but is not evidence for the efficacy of any specific
      therapy in this disorder.
- name: Genetic Counselling
  description: >
    Counselling must be framed around the semidominant X-linked pattern rather
    than a simple recessive model, because carrier females are frequently mildly
    affected and can occasionally be fully symptomatic. Carrier mothers have a 50%
    risk of transmitting the allele to each child; sons who inherit it will be
    affected, daughters who inherit it may be mildly affected. Because the
    disorder is caused by one recurrent allele, targeted testing of at-risk
    relatives is straightforward once the proband is diagnosed. The reported
    pedigrees are multiplex three- and four-generation families, so the recurrence
    risk conversation is often not hypothetical.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:11885030
    reference_title: A mutation hot spot for nonspecific X-linked mental retardation
      in the MECP2 gene causes the PPM-X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The A140V mutation was found in all affected males and all carrier females in the family."
    explanation: >
      Establishes the multiplex familial transmission and the existence of
      identifiable carrier females that the counselling model rests on.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When the mother is a known heterozygote, the risk to her offspring of inheriting the MECP2 variant is 50%."
    explanation: The GeneReviews recurrence-risk figure for MECP2 disorders.
animal_models:
- species: Mus musculus
  genotype: Mecp2 A140V knock-in (Jentarra et al. 2010 line)
  category: KNOCKIN
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  description: >
    The only animal model of this disorder, and an allele-matched one - it carries
    the same A140V substitution found in patients rather than a null allele. This
    matters, because Mecp2-null mice model the severe end of the MECP2 spectrum
    while the A140V knock-in has a normal lifespan, normal weight gain, and none of
    the seizures, tremors, breathing difficulties or kyphosis that confound
    interpretation of the null models. It therefore isolates the cognitive and
    structural consequences of the allele.

    Three phenotypes have been characterised: increased cell packing density with
    reduced dendritic complexity; reduced neuronal soma size that is
    cell-autonomous, tracks with down-regulated mTOR signalling, and is rescued in
    vitro by IGF-1; and an age-dependent electrophysiological progression from
    hippocampal hyperexcitability in young mice to combined hyperexcitability plus
    short- and long-term potentiation deficits in aged mice.

    Translational caveat: the model's authors describe it as a Rett
    syndrome/X-linked mental retardation model, and it has not been shown to
    reproduce the two features that define PPM-X clinically - psychosis and
    macroorchidism. See the HUMAN_MODEL_MISMATCH discussion.
  evidence:
  - reference: PMID:20163734
    reference_title: Abnormalities of cell packing density and dendritic complexity
      in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We report the construction and initial characterization of a mouse model expressing the A140V MeCP2 mutation."
    explanation: Establishes that the model carries the patient allele.
  - reference: PMID:20163734
    reference_title: Abnormalities of cell packing density and dendritic complexity
      in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In contrast to some MeCP2 mutation mouse models, the A140V mouse has an apparently normal lifespan and normal weight gain patterns with no obvious seizures, tremors, breathing difficulties or kyphosis."
    explanation: >
      Documents the mild, survivable character of the model, which parallels the
      survivable human male phenotype and is what makes it informative.
  - reference: PMID:24750778
    reference_title: Electrophysiological phenotypes of MeCP2 A140V mutant mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These results clearly illustrate the age-dependent abnormalities of neuronal and synaptic function in the MeCP2 A140V mutant mouse model"
    explanation: The electrophysiological characterisation of the same line.
discussions:
- discussion_id: ppmx_macroorchidism_mechanism
  prompt: >
    What causes macroorchidism in PPM-X syndrome, and is it actually a consistent
    feature of the MECP2 p.Ala140Val phenotype?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant
  rationale: >
    Macroorchidism is one of the four letters of the syndrome acronym, but it is
    the weakest-evidenced component of the entity. It appears in the 1996 founding
    description and is retained in the GeneReviews characterisation, yet none of
    the four subsequently reported A140V families - Siena, MRX79, the Belgian
    four-generation family, or the sporadic cases - reports testicular volumes or
    counts affected males with macroorchidism, and the allele-matched mouse model
    has not been examined for a testicular phenotype. No mechanism has been
    proposed linking loss of MeCP2-ATRX recruitment to testicular enlargement.
    Because macroorchidism is simultaneously the feature that names the syndrome
    and the feature that drives confusion with fragile X, the gap matters for both
    entity definition and differential diagnosis. It is the reason no frequency
    band is asserted for this phenotype.
  proposed_experiments:
  - experiment_id: exp_ppmx_orchidometry_pedigree_survey
    name: Systematic testicular volume survey across MECP2 A140V pedigrees
    description: >-
      Measure testicular volume by orchidometry or ultrasound in all postpubertal
      males from the known MECP2 p.Ala140Val pedigrees (Newcastle PPM-X, Siena,
      MRX79, Belgian four-generation family) and in reported sporadic carriers,
      reporting against age- and ancestry-matched normative data. This converts the
      qualitative founding observation into a countable phenotype with a
      denominator, which is what a frequency band would require.
    readouts:
    - name: Testicular volume relative to age-matched norms
      target: pathophysiology#MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant
      phenotype_term:
        preferred_term: Macroorchidism
        term:
          id: HP:0000053
          label: Macroorchidism
      assays:
      - preferred_term: orchidometry
      - preferred_term: scrotal ultrasonography
      direction: POSITIVE
  - experiment_id: exp_ppmx_mouse_testicular_phenotype
    name: Testicular phenotyping of the Mecp2 A140V knock-in mouse
    description: >-
      Compare testis weight, seminiferous tubule histology and Sertoli-cell counts
      in adult male Mecp2 A140V knock-in mice against wild-type littermates. The
      line has a normal lifespan, so adult reproductive phenotyping is feasible;
      no testicular readout has been reported for it.
    readouts:
    - name: Testis weight and seminiferous tubule histology
      target: pathophysiology#MECP2 p.Ala140Val Methyl-CpG-Binding Domain Variant
      phenotype_term:
        preferred_term: Macroorchidism
        term:
          id: HP:0000053
          label: Macroorchidism
      assays:
      - preferred_term: histopathology
      direction: POSITIVE
  evidence:
  - reference: PMID:8651288
    reference_title: 'PPM-X: a new X-linked mental retardation syndrome with psychosis,
      pyramidal signs, and macroorchidism maps to Xq28.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotype also includes pyramidal signs, Parkinsonian features, and macroorchidism, but there are no characteristic dysmorphic facial features."
    explanation: >
      The only primary clinical description of the testicular phenotype, and it is
      qualitative - no volumes, no counts.
- discussion_id: ppmx_entity_boundary_vs_nonsyndromic_xlid
  prompt: >
    Is PPM-X a distinct syndrome, or simply the most fully ascertained end of a
    single MECP2 p.Ala140Val phenotype that is otherwise reported as nonsyndromic
    X-linked intellectual disability?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cognitive and Neuropsychiatric Dysfunction
  rationale: >
    The same allele has been reported under three different nosological labels:
    PPM-X (a named syndrome), MRX79 (nonsyndromic X-linked intellectual
    disability), and "X-linked intellectual disability with spasticity". MONDO has
    already folded MRX79 into MONDO:0010235 as a synonym, which implicitly
    settles the question by lumping - but the lumping was nomenclatural rather
    than the result of a systematic phenotypic reassessment.

    A caution on the MONDO synonym list, which is itself a same-gene blending
    trap: MONDO:0010235 also carries "mental retardation, X-linked 16" (MRX16),
    but the MRX16 family does NOT carry A140V - Couvert and colleagues identified
    a different MECP2 allele, E137G, in that family (PMID:11309367). MRX16 was
    merged into this MONDO entity by nomenclature, not on allelic grounds, and it
    is deliberately excluded from the A140V pedigree counts and from the proposed
    experiments below. The defining psychiatric and testicular features come almost
    entirely from the single founding pedigree, while the motor phenotype
    replicates robustly across families. It is therefore unresolved whether
    psychosis and macroorchidism are allele-level features that were simply not
    looked for in the families ascertained as nonsyndromic, or genuine
    family-specific modifiers. This is a live curation question, because if the
    former is true the entity is well defined and underdiagnosed, and if the latter
    is true the honest entity is "MECP2 p.Ala140Val-related X-linked intellectual
    disability with spasticity" and PPM-X is a historically privileged pedigree.
  proposed_experiments:
  - experiment_id: exp_ppmx_blinded_psychiatric_reassessment
    name: Protocolised psychiatric reassessment of A140V pedigrees ascertained as
      nonsyndromic
    description: >-
      Apply a structured diagnostic interview for affective and psychotic episodes,
      adapted for intellectual disability, to all adult carriers in the MRX79
      family and in other A140V pedigrees originally ascertained as
      nonsyndromic, with raters blind to the historical syndrome label. If
      psychosis is found at rates comparable to the founding family, the entity is
      confirmed as underdiagnosed rather than pedigree-specific.
    readouts:
    - name: Lifetime prevalence of affective psychotic episodes
      target: pathophysiology#Cognitive and Neuropsychiatric Dysfunction
      phenotype_term:
        preferred_term: Psychosis
        term:
          id: HP:0000709
          label: Psychosis
      direction: POSITIVE
  - experiment_id: exp_ppmx_genotype_first_biobank_phenotyping
    name: Genotype-first ascertainment of MECP2 A140V carriers from sequencing biobanks
    description: >-
      Identify MECP2 c.419C>T carriers in large population and clinical sequencing
      biobanks and phenotype them prospectively, blind to the PPM-X literature.
      Genotype-first ascertainment removes the referral bias that produced the
      original syndrome definition and is the only design that can estimate the
      true penetrance of the psychiatric and testicular features.
    readouts:
    - name: Penetrance of psychosis, macroorchidism and spastic paraparesis in
        unselected carriers
      target: pathophysiology#Cognitive and Neuropsychiatric Dysfunction
      direction: POSITIVE
  evidence:
  - reference: PMID:12325019
    reference_title: 'Identification of a family with nonspecific mental retardation
      (MRX79) with the A140V mutation in the MECP2 gene: is there a need for routine
      screening?'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We mapped a new non-syndromic X-linked family (MRX79) to the chromosomal region Xq27.3-Xq28 and identified an A140V mutation in the MEPC2 gene in all patients with the disease haplotype."
    explanation: >
      The same allele described as causing explicitly non-syndromic intellectual
      disability, which is the crux of the boundary question.
  - reference: PMID:27465203
    reference_title: Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation
      family with X-linked intellectual disability and spasticity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We further delineate the phenotype associated with the p.Ala140Val mutation, illustrating a variable expressivity even within a given family, and we compare our patients with previous reported cases in the literature."
    explanation: >
      Documents variable expressivity within a family, which is the mechanism by
      which one allele could plausibly generate both the syndromic and the
      nonsyndromic presentations.
- discussion_id: ppmx_mouse_model_translational_validity
  prompt: >
    Does the Mecp2 A140V knock-in mouse model PPM-X syndrome, or does it model the
    mild end of Rett syndrome? Neither of the two features that define PPM-X
    clinically - psychosis and macroorchidism - has been demonstrated in it, and
    ATRX localisation, the proposed mechanism, has never been assayed in it.
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Disrupted Neuronal Maturation and Dendritic Arborization
  - pathophysiology#Hippocampal Network Hyperexcitability and Impaired Synaptic Plasticity
  rationale: >
    All cellular and circuit-level evidence in this entry comes from one mouse
    line, and that line is consistently framed by its own creators as a model of
    "Rett syndrome/X-linked mental retardation", with PPM-X mentioned only as one
    of the human phenotypes the allele can produce. The reported phenotypes -
    increased cell packing density, reduced dendritic complexity, reduced soma
    size, hippocampal hyperexcitability, aged-onset LTP deficits - are generic
    MeCP2-dysfunction readouts shared with null models, not PPM-X-specific ones. No
    published work has looked for a behavioural correlate of affective psychosis in
    the line, nor for a testicular phenotype, and its spastic-paraparesis status is
    not reported either. The mismatch is mechanistically meaningful rather than
    pedantic: the whole argument that PPM-X is separable from Rett rests on the
    ATRX-recruitment selectivity of the allele, which has been demonstrated only in
    vitro and in fibroblasts, and the mouse work does not test whether ATRX
    mislocalisation is what produces the phenotypes observed. Any claim in this
    entry sourced from the mouse is therefore marked MODEL_ORGANISM and is not used
    to support a human phenotype on its own.
  proposed_experiments:
  - experiment_id: exp_ppmx_atrx_localisation_in_vivo
    name: ATRX subnuclear localisation in Mecp2 A140V knock-in brain
    description: >-
      Assay ATRX localisation to pericentric heterochromatin in neurons from
      Mecp2 A140V knock-in mouse brain by immunofluorescence and chromatin
      fractionation, versus wild-type littermates. This tests whether the in vitro
      and cultured-fibroblast recruitment defect that the entire mechanistic model
      rests on actually holds in vivo in the allele-matched animal.
    readouts:
    - name: Fraction of neurons with ATRX at heterochromatic foci
      target: pathophysiology#Selective Loss of ATRX Recruitment with Preserved Methyl-CpG
        Binding
      biological_processes:
      - preferred_term: heterochromatin organization
        term:
          id: GO:0070828
          label: heterochromatin organization
        modifier: ABNORMAL
      direction: NEGATIVE
  - experiment_id: exp_ppmx_mouse_neurobehavioural_battery
    name: Psychosis-relevant and motor phenotyping of the Mecp2 A140V line
    description: >-
      Run a neurobehavioural battery on the A140V line covering (a)
      psychosis-relevant endophenotypes - prepulse inhibition, amphetamine
      sensitivity, circadian activity cycling - which have never been reported for
      this model, and (b) corticospinal motor function - rotarod, gait analysis,
      hindlimb clasping, with corticospinal tract histology - to test whether the
      mouse reproduces the most robustly replicated human feature, progressive
      spastic paraparesis. Together these determine whether the line is a PPM-X
      model or only a generic mild MeCP2 model.
    readouts:
    - name: Prepulse inhibition and amphetamine-induced hyperlocomotion
      target: pathophysiology#Cognitive and Neuropsychiatric Dysfunction
      direction: NEGATIVE
    - name: Age-dependent gait and hindlimb motor decline
      target: pathophysiology#Progressive Corticospinal and Extrapyramidal Dysfunction
      phenotype_term:
        preferred_term: Spastic paraparesis
        term:
          id: HP:0002313
          label: Spastic paraparesis
      direction: POSITIVE
  evidence:
  - reference: PMID:20163734
    reference_title: Abnormalities of cell packing density and dendritic complexity
      in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "We have identified various neurological abnormalities in this mouse model of Rett syndrome/X-linked mental retardation which may help to elucidate the manner in which MECP2 mutations cause neuronal changes resulting in mental retardation without the confounding effects of seizures, chronic hypoventilation, or other Rett syndrome associated symptoms."
    explanation: >
      Marked PARTIAL: the authors frame the line as a Rett/XLMR model and restrict
      their claim to generic MECP2-related neuronal changes, not to PPM-X-specific
      features.
  - reference: PMID:24750778
    reference_title: Electrophysiological phenotypes of MeCP2 A140V mutant mouse model.
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "which provides new insights into the understanding of the pathogenesis of Rett syndrome"
    explanation: >
      Marked PARTIAL: the electrophysiology paper explicitly frames its
      contribution as insight into Rett syndrome pathogenesis, not PPM-X, despite
      using the PPM-X allele.

📚

References & Deep Research

References

3

PMID:8651288

PPM-X: a new X-linked mental retardation syndrome with psychosis, pyramidal signs, and macroorchidism maps to Xq28.

No top-level findings curated for this source.

PMID:11885030

A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome.

No top-level findings curated for this source.

PMID:20301670

MECP2 Disorders.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

PPM-X Syndrome: Disease-Characteristics Research Report

Edison Scientific Literature 20 citations 2026-08-01T17:21:33.700016

PPM-X Syndrome: Disease-Characteristics Research Report

Executive summary and evidence boundary

PPM-X syndrome is an ultra-rare, X-linked, MECP2-related neurodevelopmental disorder formally represented as X-linked intellectual disability–psychosis–macroorchidism syndrome (MONDO:0010235). The acronym reflects the historically defining combination of pyramidal signs, psychosis, and macroorchidism, although intellectual disability, bipolar/manic-depressive illness, and sometimes parkinsonian features are also prominent. Curated disease–target evidence identifies MECP2 as the causal gene and links the entity to the foundational reports PMID 11309367, 11951158, and 16966553. (OpenTargets Search: PPM-X syndrome)

The principal molecular lesion in classic PPM-X pedigrees is the recurrent germline missense variant MECP2 p.Ala140Val (A140V). Evidence is nevertheless based on only a few families and case reports; there are no modern population cohorts, validated clinical criteria, disease-specific biomarkers, or PPM-X interventional trials. Accordingly, this report distinguishes:

Direct PPM-X evidence: human pedigrees carrying p.Ala140Val and the A140V mouse model.
MECP2-spectrum evidence: biologically informative but not automatically PPM-X-specific.
Rett-syndrome evidence: not interchangeable with PPM-X and especially unsuitable for estimating PPM-X frequencies or treatment effects.

The following table provides the principal knowledge-base annotations.

domain	syndrome-specific finding	ontology/identifier suggestion	evidence strength or caveat
Disease identity	PPM-X syndrome corresponds to X-linked intellectual disability-psychosis-macroorchidism syndrome	MONDO:0010235; disease label: X-linked intellectual disability–psychosis–macroorchidism syndrome	Strong disease-entity resolution from Open Targets disease mapping; rare-disease nomenclature remains variable across MECP2 literature (OpenTargets Search: PPM-X syndrome)
Causal gene	Disease is an MECP2-related disorder	MECP2; Ensembl ENSG00000169057	Strong gene–disease association in curated target–disease resources and historical literature linkage (OpenTargets Search: PPM-X syndrome)
Key pathogenic variant	Classic PPM-X is centered on recurrent MECP2 p.Ala140Val (A140V) missense variation	HGVS protein: p.Ala140Val	Strong historical syndrome association, but ultra-small number of pedigrees; variant-specific evidence is much narrower than for common RTT variants (OpenTargets Search: PPM-X syndrome, gold2024rettsyndrome pages 3-4)
Etiology / variant class	Germline missense variant affecting MeCP2 function	Sequence Ontology suggestion: missense_variant	Syndrome-specific primary reports exist, but most mechanistic detail comes from broader MeCP2 functional literature rather than direct PPM-X experiments (OpenTargets Search: PPM-X syndrome, lyst2013rettsyndromemutations pages 1-5, gold2024rettsyndrome pages 3-4)
Inheritance	X-linked inheritance with marked sex effects; males predominantly affected, females may be asymptomatic or milder depending in part on X-inactivation	HPO inheritance term suggestion: X-linked inheritance	Strong from syndrome name and broader MECP2 male/female literature; exact penetrance for PPM-X specifically is not well quantified (brand2021theimpactof pages 9-10, allison2024mecp2relateddisorderswhile pages 2-4)
Core phenotype: neurodevelopment	Intellectual disability / developmental impairment is a core syndrome component	HPO suggestion: Intellectual disability (HP:0001249)	Strong syndrome-defining feature; exact severity distribution for PPM-X is not robustly quantified in modern cohorts (OpenTargets Search: PPM-X syndrome, balicza2024multilevelevidenceof pages 2-3)
Core phenotype: psychiatric	Psychosis and/or bipolar/manic-depressive illness are hallmark PPM-X features distinguishing it from many other MECP2 disorders	HPO suggestions: Psychosis (HP:0000709); Bipolar affective disorder	Strong syndrome-specific historical description, but based on very few reported families/patients (OpenTargets Search: PPM-X syndrome, brand2021theimpactof pages 9-10)
Core phenotype: corticospinal	Pyramidal signs / spasticity reported in affected males	HPO suggestions: Spasticity (HP:0001257); Pyramidal signs	Moderate evidence; described as part of syndrome phenotype and later family expansion, but prevalence not well established (OpenTargets Search: PPM-X syndrome, balicza2024multilevelevidenceof pages 2-3)
Core phenotype: extrapyramidal	Parkinsonism can occur in the PPM-X/MECP2 male spectrum	HPO suggestion: Parkinsonism (HP:0001300)	Moderate evidence; likely represents part of the broader male MECP2 phenotypic spectrum rather than universal PPM-X finding (balicza2024multilevelevidenceof pages 2-3)
Core phenotype: endocrine/reproductive	Macroorchidism is part of the defining triad/name	HPO suggestion: Macroorchidism (HP:0000053)	Strong as syndrome-defining terminology, but frequency and age-dependence in all carriers are not well quantified (OpenTargets Search: PPM-X syndrome, balicza2024multilevelevidenceof pages 2-3)
Additional neurologic/behavioral features	Speech delay, social withdrawal, anxiety, learning disability, cognitive slowing, microcephaly, rigidity and other variable male MECP2 features may occur across the spectrum	HPO suggestions: Delayed speech and language development, Anxiety, Microcephaly, Rigidity	Mostly extrapolated from broader male MECP2 case literature; not all are validated as canonical PPM-X features (balicza2024multilevelevidenceof pages 2-3, allison2024mecp2relateddisorderswhile pages 2-4, gold2024rettsyndrome pages 3-4)
Molecular mechanism	Current understanding places MeCP2 in methylated-DNA binding and transcriptional regulation, especially via interaction with the NCoR/SMRT corepressor complex; MeCP2 dosage sensitivity is central	GO suggestions: DNA-binding transcriptional regulation; chromatin organization	Mechanistically strong for MECP2 biology overall, but not directly proven as the complete causal chain for PPM-X p.A140V specifically; use as informed extrapolation (balicza2024multilevelevidenceof pages 2-3, lyst2013rettsyndromemutations pages 1-5, gold2024rettsyndrome pages 3-4)
Cell type / tissue emphasis	Disease biology is expected to be primarily neuronal/CNS, with highest MeCP2 abundance in neurons	CL suggestion: neuron; UBERON suggestion: brain	Strong for MECP2 disorders generally; PPM-X-specific tissue studies are lacking (balicza2024multilevelevidenceof pages 2-3, gold2024rettsyndrome pages 3-4)
Diagnosis	Diagnosis is best established by molecular testing of MECP2 in males/families with X-linked intellectual disability plus psychiatric and neurologic features; exome/genome sequencing can help detect atypical MECP2 presentations	Gene testing target: MECP2; MONDO:0010235	Strong conceptual support; no dedicated PPM-X diagnostic guideline located. Modern sequencing is favored because male MECP2 disorders can be overlooked or mistaken for other neuropsychiatric disease (garrison2024raregeneticdiseases pages 10-13, garrison2024raregeneticdiseases pages 13-16, allison2024mecp2relateddisorderswhile pages 2-4)
Differential diagnosis / classification caveat	PPM-X should be distinguished from classic Rett syndrome, MECP2 duplication syndrome, and other male MECP2-related neurodevelopmental disorders	Related entities: RTT, MECP2 duplication syndrome	Important caveat: broader MECP2 spectrum is heterogeneous, and features in males can differ substantially from classic RTT in females (balicza2024multilevelevidenceof pages 2-3, allison2024mecp2relateddisorderswhile pages 2-4, gold2024rettsyndrome pages 3-4)
Treatment status	No PPM-X-specific disease-modifying therapy was identified; management appears supportive and symptom-directed (psychiatric, neurologic, developmental, rehabilitative, endocrine surveillance as indicated)	NCIT suggestions: supportive care / psychiatric management / rehabilitation	Evidence gap: no syndrome-specific interventional trials found. Care recommendations are inferred from rare-disease neuropsychiatric management rather than validated PPM-X protocols (garrison2024raregeneticdiseases pages 10-13, garrison2024raregeneticdiseases pages 13-16)
MECP2/Rett therapeutics relevance	Gene therapy and pathway-based Rett treatments exist in development for MECP2 disorders, but should not be considered validated for PPM-X	Caveat annotation: extrapolated MECP2 evidence	Critical distinction: Rett/MECP2-wide therapeutic data are not syndrome-specific and may not translate directly to p.A140V PPM-X because dosage and phenotype differ (collins2022rettsyndromeand pages 13-14, allison2024mecp2relateddisorderswhile pages 2-4, gold2024rettsyndrome pages 3-4)
Epidemiology	PPM-X is ultra-rare; no reliable prevalence or incidence estimate was identified	Epidemiology field: unknown / not established	Strong evidence of rarity, but no modern registry-based estimate; published knowledge is based mainly on a few families and case reports (garrison2024raregeneticdiseases pages 10-13, garrison2024raregeneticdiseases pages 13-16)
Natural history	Course appears chronic lifelong with childhood neurodevelopmental issues and later-emerging psychiatric/neurologic manifestations in some males	HPO onset suggestions: childhood onset; progressive/variable course	Moderate evidence; natural history data are sparse and mostly pedigree-based, without standardized longitudinal cohorts (balicza2024multilevelevidenceof pages 2-3)
Model organism	A syndrome-relevant Mecp2 A140V mouse model has been reported, including electrophysiological abnormalities	Model: Mecp2 A140V mutant mouse	Useful for mechanism, but still a model-system approximation of human PPM-X; does not capture the full human psychiatric phenotype (OpenTargets Search: PPM-X syndrome)
Knowledge-base evidence boundary	For curation, separate direct PPM-X evidence (few pedigrees, A140V-linked syndrome, male phenotype) from broader MECP2/Rett evidence (mechanisms, biomarkers, therapies)	Annotation suggestion: direct human evidence vs extrapolated MECP2 evidence	Essential caveat for accurate knowledge-base use: the latter is biologically informative but not disease-specific validation for PPM-X (OpenTargets Search: PPM-X syndrome, balicza2024multilevelevidenceof pages 2-3, gold2024rettsyndrome pages 3-4)

Table: This table condenses the most actionable knowledge-base facts for PPM-X syndrome, including identity, gene, variant, core phenotype domains, and evidence caveats. It is especially useful for distinguishing direct syndrome-specific evidence from broader MECP2/Rett extrapolations.

1. Disease information

Definition

PPM-X is an allelic MECP2 disorder chiefly affecting hemizygous males. Its phenotype combines developmental/cognitive impairment with later neuropsychiatric and motor-system abnormalities. It is distinct from classic Rett syndrome, severe neonatal MECP2 encephalopathy, and MECP2 duplication syndrome, although all belong to the broader MECP2-associated spectrum. Contemporary literature explicitly separates male MECP2 presentations into severe neonatal encephalopathy, PPM-X, other syndromic/nonsyndromic intellectual disability, and MECP2 duplication syndrome. (balicza2024multilevelevidenceof pages 2-3)

Identifiers and synonyms

MONDO: MONDO:0010235.
Preferred name: X-linked intellectual disability–psychosis–macroorchidism syndrome.
Synonyms: PPM-X syndrome; PPMX; X-linked intellectual disability with psychosis and macroorchidism; historically, X-linked mental retardation with psychosis, pyramidal signs/parkinsonism, and macroorchidism.
Gene: MECP2, Ensembl ENSG00000169057; methyl-CpG binding protein 2. (OpenTargets Search: PPM-X syndrome)
OMIM: commonly cross-referenced within the MECP2 allelic-disorder record MIM 300055; database implementations may not assign PPM-X a wholly independent phenotype record.
Orphanet, MeSH, ICD-10/ICD-11: no clearly validated, syndrome-specific identifier or billing code was established from the retrieved evidence. Cases will generally be coded under intellectual-developmental disorder, genetic syndrome, psychosis/bipolar disorder, or neurologic manifestations.

The evidence is aggregated disease-level literature and family reports, not an EHR-derived patient dataset. Recent health-economic analyses of rare neuropsychiatric diseases are not PPM-X-specific and must not be interpreted as syndrome epidemiology. (garrison2024raregeneticdiseases pages 10-13, garrison2024raregeneticdiseases pages 13-16)

Key primary publications

Original syndrome report: PMID 11309367; PubMed: https://pubmed.ncbi.nlm.nih.gov/11309367/
MECP2 A140V/PPM-X report: Klauck et al., American Journal of Human Genetics, April 2002, DOI https://doi.org/10.1086/339553; PMID 11951158.
Familial male MECP2 report/phenotypic expansion: PMID 16966553; https://pubmed.ncbi.nlm.nih.gov/16966553/

2. Etiology

Causal factor

PPM-X is genetic, caused principally by a germline hemizygous MECP2 missense variant, p.Ala140Val, in affected males. MECP2 is X-linked; thus one altered maternal X chromosome is sufficient to expose the allele in a son. The evidence supports an allelic MECP2 disorder rather than an infectious, toxic, nutritional, or acquired disease. (OpenTargets Search: PPM-X syndrome)

Genetic risk factors

A maternally inherited pathogenic/likely pathogenic MECP2 allele is the major risk factor.
A family history of X-linked intellectual disability, psychosis/bipolar illness, spasticity, parkinsonism, or macroorchidism increases suspicion.
Female heterozygotes may be unaffected or mildly affected because of cellular mosaicism from X-chromosome inactivation (XCI). Blood XCI does not reliably predict cerebral XCI or phenotype. (brand2021theimpactof pages 9-10)
Somatic mosaicism and 47,XXY can mitigate otherwise severe MECP2 phenotypes in males, but these mechanisms are more relevant to Rett-like male disease than to classic inherited A140V PPM-X. (balicza2024multilevelevidenceof pages 2-3)

Protective factors and modifiers

No validated PPM-X-specific protective allele, diet, exposure, medication, or lifestyle factor is known. Skewed XCI favoring the normal allele can be protective in heterozygous females, but it is a biological modifier rather than an actionable prevention strategy, and peripheral-blood XCI is an unreliable phenotype predictor. (brand2021theimpactof pages 9-10)

For MECP2 disorders generally, XCI, age, BDNF polymorphisms, background genetics, and treatment can alter severity; only XCI is immediately plausible in PPM-X carrier females, and none has been quantified in PPM-X cohorts. (gold2024rettsyndrome pages 3-4)

Environment and gene–environment interaction

No reproducible environmental cause or PPM-X-specific gene–environment interaction has been demonstrated. General psychosocial stressors, medications, sleep disruption, and medical illness may affect psychiatric or motor manifestations, but they do not cause the inherited syndrome. Claims about endocrine chemicals, valproate, or other modifiers of NCoR/HDAC biology remain general mechanistic hypotheses rather than PPM-X evidence.

3. Phenotypes

Published frequencies are unavailable; terms such as “core,” “reported,” and “variable” are more defensible than percentages.

Phenotype	Type and course	Suggested HPO term
Intellectual disability/developmental impairment	Core; begins in childhood; severity variable	Intellectual disability, HP:0001249; Global developmental delay, HP:0001263
Speech/language delay	Developmental symptom; childhood onset	Delayed speech and language development, HP:0000750
Psychosis	Defining psychiatric manifestation, often recognized later than developmental impairment	Psychosis, HP:0000709
Bipolar/manic-depressive illness	Hallmark behavioral/psychiatric feature in original pedigrees	Bipolar affective disorder, HP:0007302
Pyramidal signs/spasticity	Neurologic sign; may be progressive	Spasticity, HP:0001257; Hyperreflexia, HP:0001347
Parkinsonism/rigidity	Reported later neurologic manifestation; not necessarily universal	Parkinsonism, HP:0001300; Rigidity, HP:0002063
Macroorchidism	Defining physical sign, generally apparent after pubertal development	Macroorchidism, HP:0000053
Learning disability	Variable childhood manifestation	Specific learning disability, HP:0001328
Anxiety/social withdrawal	Variable behavioral manifestations across milder male MECP2 disease	Anxiety, HP:0000739; Social withdrawal, HP:0005407

A recent male MECP2 case—not established as classic A140V PPM-X—illustrates why spectrum evidence must be separated: speech delay and learning disabilities preceded social withdrawal at about age 10, anxiety/depression by 17, and severe anxiety, apathy, avolition, alogia, and cognitive slowing by 34. Macroorchidism was not present in that individual. (balicza2024multilevelevidenceof pages 2-3)

Quality-of-life effects

No PPM-X-specific EQ-5D, SF-36, PROMIS, caregiver-burden, or functional-outcome study was found. Intellectual disability affects education and independent functioning; psychosis or bipolar illness can impair relationships, safety, and community participation; spasticity and parkinsonism can reduce mobility and self-care. These impacts are clinically plausible but have not been quantified for PPM-X.

4. Genetic and molecular information

Gene and variant

Gene: MECP2; Xq28; HGNC symbol MECP2.
Protein: methyl-CpG-binding protein 2.
Canonical PPM-X lesion: germline missense p.Ala140Val/A140V; transcript-specific cDNA notation should be reported against the laboratory transcript, preferably both current MECP2E1 and MECP2E2 references when relevant.
Origin: inherited germline in classic pedigrees; not a tumor-associated somatic alteration.
Population frequency: no reliable frequency was established in the retrieved sources. A Brazilian screen concluded that A140V was not a common explanation for intellectual disability in males, supporting rarity rather than supplying a carrier-frequency estimate.

Variant classification should be taken from the current ClinVar submission and laboratory interpretation at the time of testing. Historical segregation and recurrence strongly support pathogenicity for the PPM-X phenotype, but ACMG/AMP classification must include transcript, segregation, population frequency, functional evidence, and phenotype specificity rather than relying on the syndrome name alone.

Protein and epigenetic biology

MeCP2 is a dosage-sensitive, predominantly neuronal nuclear protein. It binds methyl-CG and neuronal methyl-CAC sites and helps tether methylated DNA to the NCoR/SMRT transcriptional corepressor machinery through functional domains including the methyl-CpG-binding domain and NCoR-interaction region. It also influences chromatin organization, transcriptional activation/repression, splicing, and microRNA processing. (balicza2024multilevelevidenceof pages 2-3, gold2024rettsyndrome pages 3-4)

The retrieved evidence does not establish that A140V abolishes NCoR/SMRT binding. That mechanism is well demonstrated for selected Rett-causing variants and should not be assigned to A140V without variant-specific data. More generally, pathogenic MECP2 missense variants cluster in DNA-binding and NCoR-interaction domains, supporting defective chromatin-linked transcriptional regulation as a unifying mechanism. (lyst2013rettsyndromemutations pages 1-5, gold2024rettsyndrome pages 3-4)

Modifier genes, structural abnormalities, and epigenetics

No PPM-X-specific modifier gene, episignature, methylation diagnostic, translocation, inversion, or recurrent copy-number abnormality is established. MECP2 duplications cause a separate gain-of-dosage syndrome and are not PPM-X. XCI modifies expression in females, but blood-based XCI testing has limited predictive value. (brand2021theimpactof pages 9-10, collins2022rettsyndromeand pages 4-5)

5. Environmental information

No causal toxin, radiation exposure, pollutant, occupation, smoking pattern, diet, alcohol exposure, exercise pattern, or infectious agent has been implicated. PPM-X is not communicable and has no zoonotic mechanism. Environmental and lifestyle management may improve general health or reduce complications but cannot prevent expression of a hemizygous causal allele.

6. Mechanism and pathophysiology

Best-supported causal chain

Germline MECP2 p.Ala140Val → altered MeCP2 function in post-mitotic neurons → abnormal interpretation of neuronal DNA methylation/chromatin state → subtle dysregulation of many activity-dependent, synaptic, trophic, and metabolic genes → disturbed neuronal maturation and excitation–inhibition/circuit homeostasis → developmental cognitive impairment → age-dependent psychiatric and corticospinal/extrapyramidal manifestations.

The first and last links are supported directly by human genetic segregation and phenotype. Intermediate links are inferred mainly from broader MECP2 biology and the A140V mouse, not demonstrated comprehensively in human PPM-X tissue. MeCP2 is highest in neurons, lower in astrocytes and oligodendrocytes, and MECP2 disorders involve multiregional neuronal and non-cell-autonomous glial effects without classic neurodegeneration. (gold2024rettsyndrome pages 3-4)

Suggested ontology annotations

GO biological process: regulation of transcription by RNA polymerase II; chromatin organization; DNA methylation-dependent heterochromatin assembly; nervous-system development; regulation of synaptic transmission; learning or memory.
GO molecular function: methyl-CpG binding; chromatin binding; transcription-corepressor binding.
GO cellular component: nucleus; chromatin; nucleoplasm.
Cell Ontology: neuron (CL:0000540), glutamatergic neuron (CL:0000679), GABAergic neuron (CL:0000617), astrocyte (CL:0000127), oligodendrocyte (CL:0000128).

Molecular profiling and advanced technologies

No PPM-X-specific human single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, epigenomic, organoid, or CRISPR-screen dataset was identified. Recent single-cell post-mortem work in Rett syndrome shows cell-type-specific expression perturbations and supports DNA-methylation-dependent regulation, but this is MECP2 loss-of-function/Rett evidence, not direct A140V PPM-X evidence. (gold2024rettsyndrome pages 3-4)

A 2024 report of a different pathogenic male MECP2 variant found transcriptomic oxidative-phosphorylation changes, elevated exercise lactate, and muscle mitochondrial abnormalities. Its abstract states that evidence was observed at “multiple consistent levels,” but those results cannot be generalized to PPM-X without replication in A140V carriers. (balicza2024multilevelevidenceof pages 2-3)

7. Anatomical structures affected

Primary system: central nervous system, especially cerebral neuronal networks involved in cognition, behavior, mood, and motor control.
Likely motor structures: corticospinal pathways for pyramidal signs and basal-ganglia circuitry for parkinsonism; direct PPM-X neuroimaging/pathology localization is lacking.
Secondary structure: testes, manifested by macroorchidism; its cellular mechanism is unresolved.
Tissue/cell level: neurons are the best-supported primary cell population; astrocytes and oligodendrocytes are plausible contributors from broader MECP2 research.
Subcellular level: nucleus, chromatin, methylated DNA, and transcriptional-corepressor complexes.
Lateralization: no characteristic unilateral or asymmetric distribution is known.

Suggested anatomy terms include UBERON:0000955 brain, UBERON:0002280 central nervous system, UBERON:0000473 testis, cerebral cortex, corticospinal tract, and basal ganglia. MeCP2 is particularly abundant in brain neurons. (gold2024rettsyndrome pages 3-4)

8. Temporal development

PPM-X is a chronic lifelong disorder. Neurodevelopmental or learning difficulties begin in childhood; psychosis, bipolar illness, spasticity, parkinsonism, and macroorchidism may become recognizable later. A formal stage system, median onset ages, progression rate, remission rate, and critical therapeutic window have not been established.

The four-stage natural history of classic Rett syndrome—early stagnation, regression at 6–18 months, plateau, and late motor deterioration—must not be imposed on PPM-X. It describes a different MECP2 phenotype. (allison2024mecp2relateddisorderswhile pages 2-4)

9. Inheritance and population

Inheritance

Pattern: X-linked, historically described as X-linked recessive because males are more consistently affected.
Male risk: a heterozygous carrier mother has a 50% chance of transmitting the allele in each pregnancy; a son inheriting it is hemizygous, while a daughter inheriting it is heterozygous and variably affected.
Affected father: transmits his X chromosome to all daughters and no sons.
Penetrance: apparently high for neurodevelopmental manifestations in hemizygous males carrying a genuinely pathogenic family allele, but not numerically established.
Expressivity: variable, particularly for psychiatric and motor features and among females.
Anticipation: not demonstrated.
Germline mosaicism: theoretically possible for MECP2 variants, but no PPM-X-specific rate is known.
Founder effect/consanguinity: not established; consanguinity is not required for an X-linked disorder.

Epidemiology

No valid prevalence, incidence, carrier-frequency, ethnic enrichment, geographic distribution, or age-standardized mortality estimate exists. PPM-X should be classified as ultra-rare. Published knowledge derives from very few pedigrees rather than surveillance or registry data. The disease–gene association itself is supported by only a small evidence set in curated resources. (OpenTargets Search: PPM-X syndrome)

The expected clinical sex ratio is strongly male-biased, while female heterozygotes may have mild intellectual or psychiatric manifestations or remain clinically unaffected depending partly on XCI. (brand2021theimpactof pages 9-10)

10. Diagnostics

Clinical suspicion

Consider PPM-X in a male with:

developmental delay, intellectual disability, or learning disorder;
psychosis, bipolar illness, marked social withdrawal, or otherwise unexplained psychiatric deterioration;
pyramidal signs, spasticity, rigidity, or parkinsonism;
macroorchidism; and
a maternal family history compatible with X-linked transmission.

No standardized diagnostic criteria, laboratory biomarker, characteristic MRI pattern, EEG signature, biopsy finding, endocrine assay, or metabolomic profile is validated.

Molecular workflow

First line: neurodevelopmental/intellectual-disability multigene panel including MECP2, or clinical exome/genome sequencing with copy-number calling.
Variant confirmation: orthogonal confirmation of MECP2 p.Ala140Val and segregation testing in the mother and informative relatives.
Mosaicism: if suspicion remains despite negative conventional testing, use high-depth NGS and, where appropriate, targeted digital PCR; modern male MECP2 studies show that mosaic variants can be missed during lengthy diagnostic odysseys.
Copy-number analysis: exon-level deletion/duplication analysis distinguishes sequence variants from MECP2 duplication syndrome.
CMA: useful when broader syndromic intellectual disability or an Xq28 rearrangement is suspected, but it will not reliably detect a single-nucleotide A140V variant.
Karyotype/FISH: reserve for suspected large rearrangement or sex-chromosome abnormality.
RNA sequencing: potentially useful for uncertain splice variants, not routinely required for A140V.
Mitochondrial and repeat-expansion tests: not routine PPM-X tests unless the phenotype independently indicates them.

Modern expert reviews favor simultaneous multigene testing, exome/genome sequencing, and explicit mosaicism assessment for overlapping MECP2-spectrum presentations. (allison2024mecp2relateddisorderswhile pages 2-4, gold2024rettsyndrome pages 3-4)

Differential diagnosis

Classic or atypical Rett syndrome: developmental regression, hand stereotypies, gait and autonomic abnormalities, usually females.
Severe male MECP2 encephalopathy: neonatal onset and profound neurologic disease.
MECP2 duplication syndrome: hypotonia, severe developmental delay, recurrent respiratory infections, absent speech, epilepsy, and copy-number gain rather than A140V. (collins2022rettsyndromeand pages 4-5)
Fragile X syndrome: intellectual disability and macroorchidism, but FMR1 CGG expansion and a different behavioral/physical profile.
Lujan–Fryns, Christianson, alpha-thalassemia X-linked intellectual disability, and other X-linked ID syndromes.
Primary schizophrenia or bipolar disorder: lacks the syndromic developmental, neurologic, endocrine, and pedigree pattern.
Wilson disease and metabolic/neurodegenerative causes of psychiatric disease plus parkinsonism.

Screening

There is no population or newborn screen. Cascade testing is appropriate after a familial variant is found. Carrier, prenatal, and preimplantation testing are technically feasible for a known familial MECP2 variant.

11. Outcome and prognosis

No PPM-X-specific survival curve, life-expectancy estimate, mortality rate, five- or ten-year outcome, validated prognostic model, or prognostic biomarker exists. Morbidity is expected to arise from lifelong cognitive disability, psychiatric illness, and progressive or persistent motor impairment. Recovery to an unaffected state is not expected because the cause is constitutional, although psychiatric symptoms and complications may respond to treatment.

Potential prognostic variables—unsupported by quantitative PPM-X studies—include baseline cognitive severity, age at psychiatric onset, motor progression, treatment responsiveness, family support, and access to multidisciplinary care. Rett and MECP2-duplication mortality statistics should not be transferred to PPM-X.

12. Treatment

Current clinical management

There is no approved PPM-X-specific disease-modifying treatment and no evidence-based treatment algorithm. Care should be individualized through medical genetics, neurology, psychiatry, developmental medicine, rehabilitation, and primary care.

Psychosis/mania: standard antipsychotic or mood-stabilizing treatment with careful monitoring for extrapyramidal effects, sedation, metabolic toxicity, QT effects, and worsening rigidity. No PPM-X pharmacogenomic rule exists.
Anxiety/depression: psychotherapy adapted to cognitive level and cautious use of conventional medication.
Spasticity/rigidity/parkinsonism: physiotherapy, occupational therapy, mobility aids, and specialist-directed pharmacotherapy; response data are absent.
Development: individualized education, speech-language therapy, behavioral support, and supported-employment/living planning.
Macroorchidism: clinical examination and urology/endocrinology referral only if symptomatic or diagnostically uncertain; macroorchidism itself may require no intervention.
Surveillance: periodic neurologic, psychiatric, functional, sleep, nutrition, and medication-adverse-effect assessment.

Suggested NCIt intervention concepts are Supportive Care, Genetic Counseling, Physical Therapy, Occupational Therapy, Speech Therapy, Antipsychotic Therapy, and Mood Stabilizer Therapy; these are category-level annotations, not PPM-X-approved indications.

Experimental therapies and trials

No PPM-X-specific trial was identified. Rett-focused approaches—trofinetide, BDNF/IGF1-pathway modulation, ketamine, AAV-MECP2 replacement, RNA editing, and X-reactivation—cannot be considered validated PPM-X treatments. Even within Rett models, restoring MeCP2 improves but does not always fully rescue phenotypes, and excessive MECP2 creates duplication-syndrome risk. (collins2022rettsyndromeand pages 13-14, allison2024mecp2relateddisorderswhile pages 2-4)

This dosage constraint is particularly important: recent experts estimate that MECP2 below roughly 80% of normal produces deficiency phenotypes, whereas levels above approximately 140% can produce duplication-syndrome features. Those thresholds are conceptual MECP2-wide estimates, not clinical dosing targets for A140V PPM-X. (allison2024mecp2relateddisorderswhile pages 2-4)

13. Prevention

Primary prevention: no vaccine, lifestyle modification, or prophylactic medication prevents the phenotype after inheritance.
Genetic prevention options: preconception counseling, maternal carrier testing, cascade testing, preimplantation genetic testing for monogenic disease, chorionic-villus sampling, or amniocentesis after informed consent.
Secondary prevention: early molecular diagnosis may avoid prolonged psychiatric misclassification and enable developmental, psychiatric, and mobility support before complications accumulate. Rare neuropsychiatric-disease experts advocate earlier exome-based testing, particularly when conventional psychiatric treatment fails or syndromic features are present. (garrison2024raregeneticdiseases pages 10-13, garrison2024raregeneticdiseases pages 13-16)
Tertiary prevention: monitor medication toxicity, contractures/falls, nutritional problems, social isolation, and caregiver burden.
Public health/environmental measures: not applicable beyond access to rare-disease diagnosis and genetic services.

14. Other species and natural disease

No naturally occurring veterinary PPM-X syndrome, breed predisposition, wildlife reservoir, zoonotic transmission, or cross-species infectious susceptibility is known. MECP2 orthologues are evolutionarily conserved across vertebrates, but laboratory genetic models—not natural animal disease—provide the comparative evidence.

Relevant taxonomy suggestions include Homo sapiens, NCBI Taxon 9606, and Mus musculus, NCBI Taxon 10090. Veterinary-breed ontology annotations are not applicable.

15. Model organisms

A140V mouse

A Mecp2 A140V knock-in mouse is the most syndrome-relevant model. Published electrophysiological work reported altered neuronal/synaptic properties, supporting A140V as a functional—not merely associative—variant. The model is useful for studying excitation–inhibition balance, synaptic physiology, neuronal morphology, and candidate interventions.

Limitations are substantial: mouse behavior cannot reproduce human psychosis or bipolar illness directly; macroorchidism and age-dependent human motor decline may be incompletely modeled; genetic background and MeCP2 isoform expression affect phenotype.

Broader MECP2 models

Mecp2-null, conditional knockout, overexpression, patient-derived iPSC, neuronal culture, and organoid models establish that altered MeCP2 dosage affects chromatin regulation, BDNF signaling, dendritic growth, synapses, and network excitability. For example, MeCP2-deficient glutamatergic neurons show disrupted autocrine BDNF signaling, and BDNF re-expression can rescue cellular growth deficits. These are valuable pathway models but are not specific replicas of PPM-X A140V disease. (collins2022rettsyndromeand pages 13-14, gold2024rettsyndrome pages 3-4)

Recent developments, expert interpretation, and research priorities

The most authoritative recent update is the 2024 Nature Reviews Disease Primers review of Rett/MECP2 biology (published November 2024; DOI https://doi.org/10.1038/s41572-024-00568-0). It emphasizes MeCP2 dosage sensitivity, cell-type-specific transcriptional effects, neuronal methyl-CAC binding, and the therapeutic risk of overcorrection. It also notes that male MECP2 disease is broader than classic Rett, but it does not supply a modern PPM-X cohort. (gold2024rettsyndrome pages 3-4)

A February 2024 review (DOI https://doi.org/10.3389/fgene.2024.1332469) similarly stresses that opposite MECP2 dosage disorders require opposite therapeutic solutions. That principle is directly relevant to future PPM-X treatment design, even though no A140V-directed therapy exists. (allison2024mecp2relateddisorderswhile pages 2-4)

The central research needs are: an international PPM-X registry; standardized deep phenotyping of all A140V carriers; contemporary ClinVar/gnomAD reconciliation; longitudinal psychiatric and motor assessments; carrier-female XCI studies using disease-relevant models; A140V-specific chromatin, single-cell, and neuronal functional assays; and treatment studies in A140V rather than generic Mecp2-null systems.

Key conclusions for knowledge-base curation

Curate PPM-X as MONDO:0010235, a distinct, ultra-rare MECP2 p.Ala140Val-associated X-linked disorder, not as a synonym for Rett syndrome. (OpenTargets Search: PPM-X syndrome)
Assign intellectual disability, psychosis/bipolar illness, pyramidal signs/spasticity, parkinsonism, and macroorchidism, but mark frequencies as unknown.
Represent the mechanism as altered MeCP2-mediated neuronal chromatin/transcription regulation, with the intermediate pathway explicitly tagged MECP2-spectrum extrapolation. (balicza2024multilevelevidenceof pages 2-3, gold2024rettsyndrome pages 3-4)
Record diagnosis by molecular MECP2 testing and familial segregation; no biochemical or imaging biomarker is validated.
Record treatment as supportive and symptom-directed; do not annotate Rett drugs or gene therapies as established PPM-X interventions.
Mark prevalence, incidence, survival, penetrance percentage, treatment-response rates, environmental risks, protective factors, omics signatures, and PPM-X-specific clinical trials as not established.

References

(OpenTargets Search: PPM-X syndrome): Open Targets Query (PPM-X syndrome, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(gold2024rettsyndrome pages 3-4): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nature Reviews Disease Primers, Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.
(lyst2013rettsyndromemutations pages 1-5): Matthew J Lyst, Robert Ekiert, Daniel H Ebert, Cara Merusi, Jakub Nowak, Jim Selfridge, Jacky Guy, Nathaniel R Kastan, Nathaniel D Robinson, Flavia de Lima Alves, Juri Rappsilber, Michael E Greenberg, and Adrian Bird. Rett syndrome mutations abolish the interaction of mecp2 with the ncor/smrt co-repressor. Nature Neuroscience, 16:898-902, Jun 2013. URL: https://doi.org/10.1038/nn.3434, doi:10.1038/nn.3434. This article has 485 citations and is from a highest quality peer-reviewed journal.
(brand2021theimpactof pages 9-10): Boudewien A Brand, Alyssa E Blesson, and Constance L. Smith-Hicks. The impact of x-chromosome inactivation on phenotypic expression of x-linked neurodevelopmental disorders. Brain Sciences, 11:904, Jul 2021. URL: https://doi.org/10.3390/brainsci11070904, doi:10.3390/brainsci11070904. This article has 53 citations.
(allison2024mecp2relateddisorderswhile pages 2-4): Katherine Allison, Mirjana Maletic-Savatic, and Davut Pehlivan. Mecp2-related disorders while gene-based therapies are on the horizon. Frontiers in Genetics, Feb 2024. URL: https://doi.org/10.3389/fgene.2024.1332469, doi:10.3389/fgene.2024.1332469. This article has 17 citations and is from a peer-reviewed journal.
(balicza2024multilevelevidenceof pages 2-3): Peter Balicza, Andras Gezsi, Mariann Fedor, Judit C. Sagi, Aniko Gal, Noemi Agnes Varga, and Maria Judit Molnar. Multilevel evidence of mecp2-associated mitochondrial dysfunction and its therapeutic implications. Frontiers in Psychiatry, Jan 2024. URL: https://doi.org/10.3389/fpsyt.2023.1301272, doi:10.3389/fpsyt.2023.1301272. This article has 8 citations.
(garrison2024raregeneticdiseases pages 10-13): Sheldon R. Garrison, Isaac J. Siegel, Christopher R. Takala, Sarah L. Vaithilingam, Gene W. Yang, Anthony W. Zoghbi, Madeline M. Hartig, Sreya Vadapalli, and Margaret E. Anderson. Rare genetic diseases in behavioral health: a comprehensive review of therapeutic strategies and diagnostic delay for childhood through adulthood with paired economic impact analysis. Unknown journal, Nov 2024. URL: https://doi.org/10.21203/rs.3.rs-5517122/v1, doi:10.21203/rs.3.rs-5517122/v1.
(garrison2024raregeneticdiseases pages 13-16): Sheldon R. Garrison, Isaac J. Siegel, Christopher R. Takala, Sarah L. Vaithilingam, Gene W. Yang, Anthony W. Zoghbi, Madeline M. Hartig, Sreya Vadapalli, and Margaret E. Anderson. Rare genetic diseases in behavioral health: a comprehensive review of therapeutic strategies and diagnostic delay for childhood through adulthood with paired economic impact analysis. Unknown journal, Nov 2024. URL: https://doi.org/10.21203/rs.3.rs-5517122/v1, doi:10.21203/rs.3.rs-5517122/v1.
(collins2022rettsyndromeand pages 13-14): Bridget E Collins and Jeffrey L Neul. Rett syndrome and mecp2 duplication syndrome: disorders of mecp2 dosage. Neuropsychiatric Disease and Treatment, 18:2813-2835, Nov 2022. URL: https://doi.org/10.2147/ndt.s371483, doi:10.2147/ndt.s371483. This article has 92 citations and is from a peer-reviewed journal.
(collins2022rettsyndromeand pages 4-5): Bridget E Collins and Jeffrey L Neul. Rett syndrome and mecp2 duplication syndrome: disorders of mecp2 dosage. Neuropsychiatric Disease and Treatment, 18:2813-2835, Nov 2022. URL: https://doi.org/10.2147/ndt.s371483, doi:10.2147/ndt.s371483. This article has 92 citations and is from a peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

PPM-X Syndrome: Disease-Characteristics Research Report

Executive summary and evidence boundary

1. Disease information

Definition

Identifiers and synonyms

2. Etiology

Causal factor

Genetic risk factors

Protective factors and modifiers

Environment and gene–environment interaction

3. Phenotypes

Quality-of-life effects

4. Genetic and molecular information

Gene and variant

Protein and epigenetic biology

Modifier genes, structural abnormalities, and epigenetics

5. Environmental information

6. Mechanism and pathophysiology

Best-supported causal chain

Suggested ontology annotations

Molecular profiling and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

Inheritance

Epidemiology

10. Diagnostics

Clinical suspicion

Molecular workflow

Differential diagnosis

Screening

11. Outcome and prognosis

12. Treatment

Current clinical management

Experimental therapies and trials

13. Prevention

14. Other species and natural disease

15. Model organisms

A140V mouse

Broader MECP2 models

Recent developments, expert interpretation, and research priorities

Key conclusions for knowledge-base curation

Artifacts